SherryVJ的个人主页 - 老虎社区

SherryVJ

SherryVJ

seraph & smiles!

IP属地：未知

386关注

104粉丝

0主题

0勋章

2021-08-04

[Tongue]

Stocks open slightly lower after ADP private-sector payrolls data

2021-09-17

🥰🥰🥰🥰

Zoom Video Stock rose 2% in morning trading

2021-12-03

Good

Moderna stock jumped more than 5% in premarket trading

2021-11-15

$SINGAPORE EXCHANGE LIMITED(S68.SI)$Ddd

2021-09-24

Ok

Toplines Before US Market Open on Friday

2021-09-09

All Red ( Red is the colour of luck) 💋💋💋

Most of China concepts stocks fell in premarket trading

2021-09-04

Thanks ☺️

Tech lifts Nasdaq to record close but Wall Street mixed on jobs report

2021-08-30

Tell me your opinion about this news...

抱歉，原内容已删除

2021-08-13

Tell me your opinion about this news...

Toplines Before US Market Open on Friday

2021-08-12

Need support to more online 😬

抱歉，原内容已删除

2021-08-12

Friday sleep 💤

抱歉，原内容已删除

2021-08-08

Gotta

SEC Moves First DeFi Unregistered Securities Lawsuit

2021-12-10

Down

Vaccine stocks dropped in morning trading

2021-12-02

Ja

Social media stocks jumped in morning trading

2021-11-25

Up

3 Unstoppable Stocks You Can Buy Right Now for Less Than $100

2021-09-03

Up again

Meta Materials shares jumped 9.5% in premarket trading

2021-08-08

Maybe 🤔

Tesla Stock: Headed to $1,200?

2021-07-27

AMD good to buy ?

AMD Reports Earnings Tuesday. It’s All About the Data Center.

2021-07-27

Will hit always highly

Tesla sales surge 98%; company boosts margins on its less-costly electric cars

2021-07-23

Lower to 50?

Intel stock ticks lower as outlook barely clears Wall Street expectations following beat

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586426326873853","uuid":"3586426326873853","gmtCreate":1623381375220,"gmtModify":1628402107333,"name":"SherryVJ","pinyin":"sherryvj","introduction":"","introductionEn":"","signature":"seraph  & smiles!","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":104,"headSize":386,"tweetSize":373,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":699146410,"gmtCreate":1639759405628,"gmtModify":1639760513920,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Tiger","listText":"Tiger","text":"Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699146410","repostId":"1113440959","repostType":4,"repost":{"id":"1113440959","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752802,"share":"https://www.laohu8.com/m/news/1113440959?lang=&edition=full","pubTime":"2021-12-17 22:53","market":"us","language":"en","title":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113440959","media":"Tiger Newspress","summary":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown","content":"<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown&nbsp;Motors&nbsp;sliding&nbsp;6%&nbsp;and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown&nbsp;Motors&nbsp;sliding&nbsp;6%&nbsp;and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","GM":"通用汽车","LCID":"Lucid Group Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113440959","content_text":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1067,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607438496,"gmtCreate":1639576827511,"gmtModify":1639576828652,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;","listText":"[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;","text":"[Shy] [Shy] [Shy] [Shy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607438496","repostId":"1148643584","repostType":4,"repost":{"id":"1148643584","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639575903,"share":"https://www.laohu8.com/m/news/1148643584?lang=&edition=full","pubTime":"2021-12-15 21:45","market":"us","language":"en","title":"U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=1148643584","media":"Tiger Newspress","summary":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at","content":"<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p>\n<p></p>\n<p>Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p>\n<p>The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly&nbsp;rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p>\n<p><b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p>\n<p>The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p>\n<p>The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p>\n<p><b>Market reaction:</b>&nbsp;The Dow Jones Industrial Average&nbsp;and S&amp;P 500 were set to open slightly lower in Wednesday trades.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. retail sales climb tepid 0.3% in November as Americans confront high inflation \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p>\n<p></p>\n<p>Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p>\n<p>The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly&nbsp;rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p>\n<p><b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p>\n<p>The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p>\n<p>The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p>\n<p><b>Market reaction:</b>&nbsp;The Dow Jones Industrial Average&nbsp;and S&amp;P 500 were set to open slightly lower in Wednesday trades.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148643584","content_text":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.\n\nEconomists polled by The Wall Street Journal had forecast a 0.8% increase.\nThe increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly rate of inflation to a 39-year high of 6.8%. Adjusted for inflation retail sales appeared to have declined.\nBig picture: Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.\nThe big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.\nThe Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.\nMarket reaction: The Dow Jones Industrial Average and S&P 500 were set to open slightly lower in Wednesday trades.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604535094,"gmtCreate":1639409933242,"gmtModify":1639411184498,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Oh my con","listText":"Oh my con","text":"Oh my con","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604535094","repostId":"1167465214","repostType":4,"repost":{"id":"1167465214","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639406352,"share":"https://www.laohu8.com/m/news/1167465214?lang=&edition=full","pubTime":"2021-12-13 22:39","market":"us","language":"en","title":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share","url":"https://stock-news.laohu8.com/highlight/detail?id=1167465214","media":"Tiger Newspress","summary":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.Pfi","content":"<p>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.<img src=\"https://static.tigerbbs.com/baca4cde05c414b1c77aa618108489b1\" tg-width=\"774\" tg-height=\"568\" width=\"100%\" height=\"auto\">Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.</p>\n<p>Pfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.</p>\n<p>Arena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.</p>\n<p>Pfizer said it expects to finance the transaction with cash on hand.</p>\n<p>Pfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.<img src=\"https://static.tigerbbs.com/baca4cde05c414b1c77aa618108489b1\" tg-width=\"774\" tg-height=\"568\" width=\"100%\" height=\"auto\">Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.</p>\n<p>Pfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.</p>\n<p>Arena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.</p>\n<p>Pfizer said it expects to finance the transaction with cash on hand.</p>\n<p>Pfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","ARNA":"阿里那"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167465214","content_text":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.\nPfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.\nArena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.\nPfizer said it expects to finance the transaction with cash on hand.\nPfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.","news_type":1},"isVote":1,"tweetType":1,"viewCount":841,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500439,"gmtCreate":1639186173290,"gmtModify":1639186174334,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605500439","repostId":"1199826178","repostType":4,"repost":{"id":"1199826178","kind":"news","pubTimestamp":1639149380,"share":"https://www.laohu8.com/m/news/1199826178?lang=&edition=full","pubTime":"2021-12-10 23:16","market":"us","language":"en","title":"Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1199826178","media":"Bloomberg","summary":"Funds and researchers are scrutinized by Justice Department. Inquiry seeks information on trading in several dozen stocks. The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.The probe, run by the department’s fraud section with federal pro","content":"<ul>\n <li>Funds and researchers are scrutinized by Justice Department</li>\n <li>Inquiry seeks information on trading in several dozen stocks</li>\n</ul>\n<p>The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.</p>\n<p>The probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.</p>\n<p>Authorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.</p>\n<p>Underscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as&nbsp;Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc&nbsp;and&nbsp;GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based&nbsp;Anson Funds&nbsp;and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.</p>\n<p>The U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds&nbsp;threw in the towel&nbsp;as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.</p>\n<p>Meanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.</p>\n<p>Still, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.</p>\n<p>Government attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.</p>\n<p>Spokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.</p>\n<p>An attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.</p>\n<p>“Citron Capital&nbsp;and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”</p>\n<p><b>Funding Research</b></p>\n<p>Hedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said&nbsp;he partnered with a hedge fund to share profits when he released a report on&nbsp;General Electric Co.</p>\n<p>Some hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.</p>\n<p>One cautionary tale emerged in court after Dallas-based&nbsp;Sabrepoint Capital&nbsp;agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company&nbsp;Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.</p>\n<p>Mathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.</p>\n<p>Farmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.</p>\n<p>The Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase &amp; Co.&nbsp;paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.</p>\n<p>While prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.</p>\n<p>The inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of&nbsp;GameStop Corp.&nbsp;soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.</p>\n<p>Lawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.</p>\n<p>Concerns about how short sellers carry out attacks have arisen repeatedly over the years.</p>\n<p>The Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.</p>\n<p>But there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.</p>\n<p>Studies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.</p>\n<p>Mitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.</p>\n<p>Academics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.</p>\n<p>Early last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Funds Ensnared in Expansive DOJ Probe Into Short Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BANC":"BANC OF CALIFORNIA","GOTU":"高途",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","MNKKQ":"Mallinckrodt plc.","LKNCY":"瑞幸咖啡","GME":"游戏驿站",".DJI":"道琼斯","GE":"GE航空航天","FPI":"Farmland Partners Inc"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199826178","content_text":"Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.\nThe probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.\nAuthorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.\nUnderscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc and GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based Anson Funds and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.\nThe U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds threw in the towel as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.\nMeanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.\nStill, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.\nGovernment attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.\nSpokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.\nAn attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.\n“Citron Capital and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”\nFunding Research\nHedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said he partnered with a hedge fund to share profits when he released a report on General Electric Co.\nSome hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.\nOne cautionary tale emerged in court after Dallas-based Sabrepoint Capital agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.\nMathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.\nFarmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.\nThe Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase & Co. paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.\nWhile prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.\nThe inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of GameStop Corp. soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.\nLawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.\nConcerns about how short sellers carry out attacks have arisen repeatedly over the years.\nThe Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.\nBut there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.\nStudies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.\nMitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.\nAcademics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.\nEarly last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500663,"gmtCreate":1639186160836,"gmtModify":1639186161876,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"✅&nbsp;","listText":"✅&nbsp;","text":"✅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605500663","repostId":"2190767366","repostType":4,"isVote":1,"tweetType":1,"viewCount":811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605857916,"gmtCreate":1639147777266,"gmtModify":1639147778334,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605857916","repostId":"1100115506","repostType":4,"repost":{"id":"1100115506","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639138188,"share":"https://www.laohu8.com/m/news/1100115506?lang=&edition=full","pubTime":"2021-12-10 20:09","market":"us","language":"en","title":"Some vaccine stocks dropped in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1100115506","media":"Tiger Newspress","summary":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell","content":"<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some vaccine stocks dropped in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome vaccine stocks dropped in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100115506","content_text":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":933,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605854787,"gmtCreate":1639147765076,"gmtModify":1639147766866,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Down&nbsp;","listText":"Down&nbsp;","text":"Down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605854787","repostId":"1148141788","repostType":4,"repost":{"id":"1148141788","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639147224,"share":"https://www.laohu8.com/m/news/1148141788?lang=&edition=full","pubTime":"2021-12-10 22:40","market":"us","language":"en","title":"Vaccine stocks dropped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148141788","media":"Tiger Newspress","summary":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","content":"<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks dropped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks dropped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148141788","content_text":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602484310,"gmtCreate":1639058002940,"gmtModify":1639058940759,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Go&nbsp;","listText":"Go&nbsp;","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602484310","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohu8.com/m/news/1129645066?lang=&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p>\n<p><img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p>\n<p>In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p>\n<p>\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p>\n<p>The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p>\n<p><img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p>\n<p>In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p>\n<p>\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p>\n<p>The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1},"isVote":1,"tweetType":1,"viewCount":922,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602915546,"gmtCreate":1638956253196,"gmtModify":1638956689133,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602915546","repostId":"1136716851","repostType":4,"repost":{"id":"1136716851","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638955203,"share":"https://www.laohu8.com/m/news/1136716851?lang=&edition=full","pubTime":"2021-12-08 17:20","market":"us","language":"en","title":"Some Vaccine stocks corrected in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1136716851","media":"Tiger Newspress","summary":"Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell betwe","content":"<p>Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech&nbsp;SE,Moderna&nbsp;and&nbsp;Pfizer&nbsp;fell&nbsp;between 3% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/b5fc2db6a961be0363c3be880585ad0f\" tg-width=\"404\" tg-height=\"241\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Vaccine stocks corrected in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Vaccine stocks corrected in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech&nbsp;SE,Moderna&nbsp;and&nbsp;Pfizer&nbsp;fell&nbsp;between 3% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/b5fc2db6a961be0363c3be880585ad0f\" tg-width=\"404\" tg-height=\"241\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136716851","content_text":"Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell between 3% and 7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504712,"gmtCreate":1638890080088,"gmtModify":1638890089373,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"999","listText":"999","text":"999","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606504712","repostId":"1107798974","repostType":4,"repost":{"id":"1107798974","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638889130,"share":"https://www.laohu8.com/m/news/1107798974?lang=&edition=full","pubTime":"2021-12-07 22:58","market":"us","language":"en","title":"777 Partners Orders 30 Additional 737 MAX Airplanes","url":"https://stock-news.laohu8.com/highlight/detail?id=1107798974","media":"Tiger Newspress","summary":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners","content":"<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p>\n<p><img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Boeing&nbsp;and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p>\n<p>\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p>\n<p>The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p>\n<p>\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>777 Partners Orders 30 Additional 737 MAX Airplanes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n777 Partners Orders 30 Additional 737 MAX Airplanes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p>\n<p><img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Boeing&nbsp;and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p>\n<p>\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p>\n<p>The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p>\n<p>\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107798974","content_text":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.\n\nBoeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.\n\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"\nThe 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.\n\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504688,"gmtCreate":1638890062281,"gmtModify":1638890088126,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606504688","repostId":"2189476639","repostType":4,"repost":{"id":"2189476639","kind":"highlight","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","BK4548":"巴美列捷福持仓","BK4528":"SaaS概念","BK4023":"应用软件","PFE":"辉瑞","BK4516":"特朗普概念","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","CRM":"赛富时","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4527":"明星科技股","BK4538":"云计算","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4115":"综合电信业务","VZ":"威瑞森","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606898447,"gmtCreate":1638851130355,"gmtModify":1638851131288,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","text":"$Twitter(TWTR)$เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","images":[{"img":"https://static.tigerbbs.com/6da83692b0f892c9884037c615ca74bd","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606898447","isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":606149768,"gmtCreate":1638846484378,"gmtModify":1638846486449,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606149768","repostId":"1186134052","repostType":4,"repost":{"id":"1186134052","kind":"news","pubTimestamp":1638843447,"share":"https://www.laohu8.com/m/news/1186134052?lang=&edition=full","pubTime":"2021-12-07 10:17","market":"us","language":"en","title":"RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147","url":"https://stock-news.laohu8.com/highlight/detail?id=1186134052","media":"InvestorPlace","summary":"Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed","content":"<p>Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week&nbsp;<b>Rivian Automative</b>(NASDAQ:<b><u>RIVN</u></b>) had a rough go. RIVN stock dropped by 12% over the course of the week.</p>\n<p>However, things are turning around today as&nbsp;<b>Morgan Stanley</b>(NYSE:<b><u>MS</u></b>)initiated coverage&nbsp;on RIVN stock with an overweight rating and a $147 price target. This price target represents an upside of 34% from current prices. In response, shares of RIVN stock are trading higher by 4%.</p>\n<p>Let’s take a look at the details of this new price prediction.</p>\n<p>RIVN Price Prediction: Is Rivian “The One” to Challenge Tesla?</p>\n<p>Morgan Stanley analyst Adam Jonas led the initiation coverage on Rivian. However, it wasn’t necessarily the price target that attracted the most attention. It was Jonas’ comment on Rivian competitor&nbsp;<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) that surprised many investors:</p>\n<blockquote>\n “Rivian’s compelling product, strong management, and deterministic access to capital are underpinned by a strategic relationship with AMZN to decarbonize the final mile. We see it as ‘the one’ that can challenge Tesla.”\n</blockquote>\n<p>A direct comparison between the two EV makers seems far off for now. However, Rivian may have the one-up on Tesla in terms of delivery vans. Jonas calls Rivian’s delivery vans “the most capable/desirable product in the market for $80k.” While Tesla has yet to enter the delivery van market, its strength lies in selling EVs directly to consumers.</p>\n<p>On that note, Rivian launched its highly anticipated R1T pickup truck this year after supply chain delays. Deliveries for the pickup truck have started, although many customers who preordered are reporting that they&nbsp;won’t receive their order until 2022. Prices start at $67,5o0 for the base R1T model.</p>\n<p>According to&nbsp;<i>Tipranks</i>,&nbsp;Adam Jonas&nbsp;has a 57% success rate and an average return of 14.5% during a one-year period. Jonas is a highly regarded analyst and ranks at 465 out of the 7,727 total analysts that<i>Tipranks</i>tracks.</p>\n<p>The Bottom Line on Rivian</p>\n<p>Rivian remains a speculative investment with high future expectations. While Rivian has reported $0 in revenue for the trailing-12-month (TTM) period, the EV maker boasts an impressive ally in&nbsp;<b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>). Amazon is Rivian’s largest customer and owns roughly 20% of the company. Furthermore, the e-commerce giant has a massive pre-order for 100,000 delivery vans that is set to be completed by 2025. Analyst Adam Jonas believes the pre-order figure will increase to 300,000.</p>\n<p>As of now, valuation, scalability and execution by management remain the biggest concerns. Before making an investment, investors need to sit down and rationalize whether Rivian can make enough deliveries in the future to support its current sky-high market capitalization of $90 billion.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 10:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course...</p>\n\n<a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186134052","content_text":"Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course of the week.\nHowever, things are turning around today as Morgan Stanley(NYSE:MS)initiated coverage on RIVN stock with an overweight rating and a $147 price target. This price target represents an upside of 34% from current prices. In response, shares of RIVN stock are trading higher by 4%.\nLet’s take a look at the details of this new price prediction.\nRIVN Price Prediction: Is Rivian “The One” to Challenge Tesla?\nMorgan Stanley analyst Adam Jonas led the initiation coverage on Rivian. However, it wasn’t necessarily the price target that attracted the most attention. It was Jonas’ comment on Rivian competitor Tesla(NASDAQ:TSLA) that surprised many investors:\n\n “Rivian’s compelling product, strong management, and deterministic access to capital are underpinned by a strategic relationship with AMZN to decarbonize the final mile. We see it as ‘the one’ that can challenge Tesla.”\n\nA direct comparison between the two EV makers seems far off for now. However, Rivian may have the one-up on Tesla in terms of delivery vans. Jonas calls Rivian’s delivery vans “the most capable/desirable product in the market for $80k.” While Tesla has yet to enter the delivery van market, its strength lies in selling EVs directly to consumers.\nOn that note, Rivian launched its highly anticipated R1T pickup truck this year after supply chain delays. Deliveries for the pickup truck have started, although many customers who preordered are reporting that they won’t receive their order until 2022. Prices start at $67,5o0 for the base R1T model.\nAccording to Tipranks, Adam Jonas has a 57% success rate and an average return of 14.5% during a one-year period. Jonas is a highly regarded analyst and ranks at 465 out of the 7,727 total analysts thatTiprankstracks.\nThe Bottom Line on Rivian\nRivian remains a speculative investment with high future expectations. While Rivian has reported $0 in revenue for the trailing-12-month (TTM) period, the EV maker boasts an impressive ally in Amazon(NASDAQ:AMZN). Amazon is Rivian’s largest customer and owns roughly 20% of the company. Furthermore, the e-commerce giant has a massive pre-order for 100,000 delivery vans that is set to be completed by 2025. Analyst Adam Jonas believes the pre-order figure will increase to 300,000.\nAs of now, valuation, scalability and execution by management remain the biggest concerns. Before making an investment, investors need to sit down and rationalize whether Rivian can make enough deliveries in the future to support its current sky-high market capitalization of $90 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608710604,"gmtCreate":1638788963960,"gmtModify":1638788968330,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Downstairs&nbsp;","listText":"Downstairs&nbsp;","text":"Downstairs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608710604","repostId":"2138143109","repostType":4,"repost":{"id":"2138143109","kind":"highlight","pubTimestamp":1622042760,"share":"https://www.laohu8.com/m/news/2138143109?lang=&edition=full","pubTime":"2021-05-26 23:26","market":"us","language":"en","title":"Why American Eagle Outfitters Is Jumping 5.5% Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2138143109","media":"Motley Fool","summary":"The apparel retailer has strong tailwinds behind it.","content":"<h2>What happened</h2><p>Shares of <b>American Eagle Outfitters</b> (NYSE:AEO) were up 5.5% in morning trading Wednesday ahead of the apparel retailer reporting first-quarter earnings after the market closes.</p><h2>So what</h2><p>Many retailers are posting strong quarterly financials as they go up against comparatively weak comparable sales from the year-ago period, which was partially marred by the coronavirus pandemic outbreak. Both <b>Abercrombie &amp; Fitch</b> and <b><a href=\"https://laohu8.com/S/URBN\">Urban Outfitters</a></b> just handily beat estimates.</p><p>Investors might view American Eagle as prepared to beat analyst expectations on the strength of its Aerie loungewear brand, which has been a strong performer throughout. Especially as working from home became an imperative for many -- and still is -- comfortable clothes that met various fashion needs became de rigueur for consumers.</p><p>Analysts expect Aerie to become a $2 billion to $3 billion brand, and it already accounts for 40% American Eagle's sales.</p><h2>Now what</h2><p>Wall Street expects American Eagle to post revenue of $1.02 billion, up 85% over the year-ago quarter, generating earnings of $0.47 per share compared to an adjusted loss of $0.84 per share (analyst estimates typically don't include <a href=\"https://laohu8.com/S/AONE\">one</a>-time items that companies end up adjusting their results for).</p><p>It already looks as though American Eagle is expected to post robust results, so the market will end up reacting tomorrow to just how much the retailer beats (or misses) those forecasts.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why American Eagle Outfitters Is Jumping 5.5% Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy American Eagle Outfitters Is Jumping 5.5% Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 23:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/26/why-american-eagle-outfitters-is-jumping-55-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of American Eagle Outfitters (NYSE:AEO) were up 5.5% in morning trading Wednesday ahead of the apparel retailer reporting first-quarter earnings after the market closes.So whatMany...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/26/why-american-eagle-outfitters-is-jumping-55-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EGBN":"伊格尔合众银行","AFG":"美国金融集团有限公司","AEO":"美鹰服饰"},"source_url":"https://www.fool.com/investing/2021/05/26/why-american-eagle-outfitters-is-jumping-55-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138143109","content_text":"What happenedShares of American Eagle Outfitters (NYSE:AEO) were up 5.5% in morning trading Wednesday ahead of the apparel retailer reporting first-quarter earnings after the market closes.So whatMany retailers are posting strong quarterly financials as they go up against comparatively weak comparable sales from the year-ago period, which was partially marred by the coronavirus pandemic outbreak. Both Abercrombie & Fitch and Urban Outfitters just handily beat estimates.Investors might view American Eagle as prepared to beat analyst expectations on the strength of its Aerie loungewear brand, which has been a strong performer throughout. Especially as working from home became an imperative for many -- and still is -- comfortable clothes that met various fashion needs became de rigueur for consumers.Analysts expect Aerie to become a $2 billion to $3 billion brand, and it already accounts for 40% American Eagle's sales.Now whatWall Street expects American Eagle to post revenue of $1.02 billion, up 85% over the year-ago quarter, generating earnings of $0.47 per share compared to an adjusted loss of $0.84 per share (analyst estimates typically don't include one-time items that companies end up adjusting their results for).It already looks as though American Eagle is expected to post robust results, so the market will end up reacting tomorrow to just how much the retailer beats (or misses) those forecasts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601790846,"gmtCreate":1638556737583,"gmtModify":1638556738033,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"😢","listText":"😢","text":"😢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601790846","repostId":"1195177271","repostType":4,"repost":{"id":"1195177271","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638542957,"share":"https://www.laohu8.com/m/news/1195177271?lang=&edition=full","pubTime":"2021-12-03 22:49","market":"us","language":"en","title":"Hot chinese concept stocks dipped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1195177271","media":"Tiger Newspress","summary":"Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.","content":"<p>Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.</p>\n<p><img src=\"https://static.tigerbbs.com/364eb167dd032a1d1046b0f329d247db\" tg-width=\"402\" tg-height=\"666\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot chinese concept stocks dipped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot chinese concept stocks dipped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-03 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.</p>\n<p><img src=\"https://static.tigerbbs.com/364eb167dd032a1d1046b0f329d247db\" tg-width=\"402\" tg-height=\"666\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","PDD":"拼多多","BABA":"阿里巴巴","BEKE":"贝壳","JD":"京东","BIDU":"百度","DIDI":"滴滴(已退市)","NIO":"蔚来","NTES":"网易","BILI":"哔哩哔哩","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195177271","content_text":"Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601210045,"gmtCreate":1638533688808,"gmtModify":1638533703139,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601210045","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohu8.com/m/news/1144924535?lang=&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p>\n<p>Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p>\n<p>Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603553063,"gmtCreate":1638431137685,"gmtModify":1638431139320,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603553063","repostId":"1197973971","repostType":4,"repost":{"id":"1197973971","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638429281,"share":"https://www.laohu8.com/m/news/1197973971?lang=&edition=full","pubTime":"2021-12-02 15:14","market":"us","language":"en","title":"Glaxo says its vaccine retains activity against key Omicron mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973971","media":"Tiger Newspress","summary":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint ser","content":"<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo says its vaccine retains activity against key Omicron mutations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo says its vaccine retains activity against key Omicron mutations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197973971","content_text":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, PhD, Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout sotrovimab\nSotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development programme\n\nCOMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon 27 October 2021 and final data were pre-published on 8 November 2021 onmedRxiv.\nCOMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe\nCOVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United States\nThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized Use\nThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized Use\nSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout the GSK and Vir collaboration\nIn April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSK commitment to tackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.\nGSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’s commitment to COVID-19\nVir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603296703,"gmtCreate":1638410588424,"gmtModify":1638411653816,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Wow nice&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Wow nice&nbsp;","text":"$NIO Inc.(NIO)$Wow nice","images":[{"img":"https://static.tigerbbs.com/3a0591c0af408d2bcb44249410443119","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603296703","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":603296500,"gmtCreate":1638410565001,"gmtModify":1638411652143,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Bit by bit&nbsp;","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Bit by bit&nbsp;","text":"$Twitter(TWTR)$Bit by bit","images":[{"img":"https://static.tigerbbs.com/b931c06a48ec84e2f073e462cba6d3a2","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603296500","isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":603206701,"gmtCreate":1638409788671,"gmtModify":1638410379523,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603206701","repostId":"1187224831","repostType":4,"isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":890329059,"gmtCreate":1628084347171,"gmtModify":1633753769296,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"[Tongue]&nbsp;","listText":"[Tongue]&nbsp;","text":"[Tongue]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/890329059","repostId":"1146704714","repostType":4,"repost":{"id":"1146704714","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628083681,"share":"https://www.laohu8.com/m/news/1146704714?lang=&edition=full","pubTime":"2021-08-04 21:28","market":"us","language":"en","title":"Stocks open slightly lower after ADP private-sector payrolls data","url":"https://stock-news.laohu8.com/highlight/detail?id=1146704714","media":"Tiger Newspress","summary":"Stocks open slightly lower after ADP private-sector payrolls data\nAirline stocks, bank stocks fell. ","content":"<ul>\n <li>Stocks open slightly lower after ADP private-sector payrolls data</li>\n <li>Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</li>\n <li>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.</li>\n</ul>\n<p>(Aug 4)&nbsp;U.S. stocks fell on Wednesday morning after the earnings of a major automaker and a private sector jobs report came in lower than expected.</p>\n<p>The Dow Jones Industrial Average shed about 147 points, or 0.4%. The S&amp;P 500 slipped by 0.3% while the Nasdaq Composite was flat. The dip comes after the S&amp;P 500 broke a 2-day losing streak on Tuesday to post a record close, bringing its 2021 gains to more than 17%.&nbsp;</p>\n<p>Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f07059e6f35af7ae40b84ff4fccdc425\" tg-width=\"364\" tg-height=\"369\" referrerpolicy=\"no-referrer\"><span>Airline stocks fell</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1616caf96bbfd7781bd83ec905dadfb4\" tg-width=\"359\" tg-height=\"652\" referrerpolicy=\"no-referrer\"><span>Bank stocks are down</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/342fe79f0fe76a05734e9a553bf3d22e\" tg-width=\"365\" tg-height=\"715\" referrerpolicy=\"no-referrer\"><span>Chinese Stocks rally</span></p>\n<p>Novavax Stock Jumps After Europe Approves Contract for Covid Vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/3da91666091c7ee912199acb975944a2\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.&nbsp;</b>Shares of General Motors fell about 6% in early trading, weighing on the broader market, after the automakermissed earnings expectations for the second quarter. The automaker did raise its guidance for a key profit metric for the rest of the year.</p>\n<p><img src=\"https://static.tigerbbs.com/a83eef22ad4c7b4513849130b478e6b7\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks open slightly lower after ADP private-sector payrolls data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks open slightly lower after ADP private-sector payrolls data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-04 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Stocks open slightly lower after ADP private-sector payrolls data</li>\n <li>Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</li>\n <li>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.</li>\n</ul>\n<p>(Aug 4)&nbsp;U.S. stocks fell on Wednesday morning after the earnings of a major automaker and a private sector jobs report came in lower than expected.</p>\n<p>The Dow Jones Industrial Average shed about 147 points, or 0.4%. The S&amp;P 500 slipped by 0.3% while the Nasdaq Composite was flat. The dip comes after the S&amp;P 500 broke a 2-day losing streak on Tuesday to post a record close, bringing its 2021 gains to more than 17%.&nbsp;</p>\n<p>Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f07059e6f35af7ae40b84ff4fccdc425\" tg-width=\"364\" tg-height=\"369\" referrerpolicy=\"no-referrer\"><span>Airline stocks fell</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1616caf96bbfd7781bd83ec905dadfb4\" tg-width=\"359\" tg-height=\"652\" referrerpolicy=\"no-referrer\"><span>Bank stocks are down</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/342fe79f0fe76a05734e9a553bf3d22e\" tg-width=\"365\" tg-height=\"715\" referrerpolicy=\"no-referrer\"><span>Chinese Stocks rally</span></p>\n<p>Novavax Stock Jumps After Europe Approves Contract for Covid Vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/3da91666091c7ee912199acb975944a2\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.&nbsp;</b>Shares of General Motors fell about 6% in early trading, weighing on the broader market, after the automakermissed earnings expectations for the second quarter. The automaker did raise its guidance for a key profit metric for the rest of the year.</p>\n<p><img src=\"https://static.tigerbbs.com/a83eef22ad4c7b4513849130b478e6b7\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146704714","content_text":"Stocks open slightly lower after ADP private-sector payrolls data\nAirline stocks, bank stocks fell. Chinese Stocks rally.\nGM fell over 6% as earnings disappoint.\n\n(Aug 4) U.S. stocks fell on Wednesday morning after the earnings of a major automaker and a private sector jobs report came in lower than expected.\nThe Dow Jones Industrial Average shed about 147 points, or 0.4%. The S&P 500 slipped by 0.3% while the Nasdaq Composite was flat. The dip comes after the S&P 500 broke a 2-day losing streak on Tuesday to post a record close, bringing its 2021 gains to more than 17%. \nAirline stocks, bank stocks fell. Chinese Stocks rally.\nAirline stocks fell\nBank stocks are down\nChinese Stocks rally\nNovavax Stock Jumps After Europe Approves Contract for Covid Vaccine.\n\nGM fell over 6% as earnings disappoint. Shares of General Motors fell about 6% in early trading, weighing on the broader market, after the automakermissed earnings expectations for the second quarter. The automaker did raise its guidance for a key profit metric for the rest of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884672632,"gmtCreate":1631890123326,"gmtModify":1632805531773,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"🥰🥰🥰🥰","listText":"🥰🥰🥰🥰","text":"🥰🥰🥰🥰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884672632","repostId":"1172069384","repostType":4,"repost":{"id":"1172069384","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631888749,"share":"https://www.laohu8.com/m/news/1172069384?lang=&edition=full","pubTime":"2021-09-17 22:25","market":"us","language":"en","title":"Zoom Video Stock rose 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1172069384","media":"Tiger Newspress","summary":"Zoom Video Stock rose 2% in morning trading on report ISS urged Five9 holders to reject takeover bid","content":"<p>Zoom Video Stock rose 2% in morning trading&nbsp;on report ISS urged Five9 holders to reject takeover bid.</p>\n<p><img src=\"https://static.tigerbbs.com/0848666fe26a30e300c95e7d49279fb1\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Proxy advisory firm Institutional Shareholder Services on Friday recommended a vote by shareholders against&nbsp;Zoom&nbsp;Video Communications Inc's $14.7 billion deal for cloud-based call center operator&nbsp;Five9 Inc, citing growth concerns.</p>\n<p>Though the combined company will have access to a larger market,ISS&nbsp;said, \"The all-stock deal exposes Five9 shareholders to a more volatile stock whose growth prospects have become less compelling as society inches towards a post-pandemic environment.\"</p>\n<p>Since the deal was announced on July 18, Zoom shares have lost more than 20% of their value, while Five9 has dipped about 5%.</p>\n<p>A pandemic winner whose shares had surged nearly 396% last year, Zoom struck its largest-ever acquisition for Five9 in a bid to expand beyond its core video-conferencing services.</p>\n<p>The company earlier this month announced improvements and expansions to its services that included event lobbies, chat, networking in the hope that consumers will continue to use its platform for remote-working.</p>\n<p>However, ISS said the new additions failed to assuage shareholder concerns of continued business churn, while Five9's prospects have improved since the acquisition was announced and could attract more bidders if the deal falls apart.</p>\n<p>Zoom and Five9 were not immediately available for a comment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video Stock rose 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video Stock rose 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-17 22:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zoom Video Stock rose 2% in morning trading&nbsp;on report ISS urged Five9 holders to reject takeover bid.</p>\n<p><img src=\"https://static.tigerbbs.com/0848666fe26a30e300c95e7d49279fb1\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Proxy advisory firm Institutional Shareholder Services on Friday recommended a vote by shareholders against&nbsp;Zoom&nbsp;Video Communications Inc's $14.7 billion deal for cloud-based call center operator&nbsp;Five9 Inc, citing growth concerns.</p>\n<p>Though the combined company will have access to a larger market,ISS&nbsp;said, \"The all-stock deal exposes Five9 shareholders to a more volatile stock whose growth prospects have become less compelling as society inches towards a post-pandemic environment.\"</p>\n<p>Since the deal was announced on July 18, Zoom shares have lost more than 20% of their value, while Five9 has dipped about 5%.</p>\n<p>A pandemic winner whose shares had surged nearly 396% last year, Zoom struck its largest-ever acquisition for Five9 in a bid to expand beyond its core video-conferencing services.</p>\n<p>The company earlier this month announced improvements and expansions to its services that included event lobbies, chat, networking in the hope that consumers will continue to use its platform for remote-working.</p>\n<p>However, ISS said the new additions failed to assuage shareholder concerns of continued business churn, while Five9's prospects have improved since the acquisition was announced and could attract more bidders if the deal falls apart.</p>\n<p>Zoom and Five9 were not immediately available for a comment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172069384","content_text":"Zoom Video Stock rose 2% in morning trading on report ISS urged Five9 holders to reject takeover bid.\n\nProxy advisory firm Institutional Shareholder Services on Friday recommended a vote by shareholders against Zoom Video Communications Inc's $14.7 billion deal for cloud-based call center operator Five9 Inc, citing growth concerns.\nThough the combined company will have access to a larger market,ISS said, \"The all-stock deal exposes Five9 shareholders to a more volatile stock whose growth prospects have become less compelling as society inches towards a post-pandemic environment.\"\nSince the deal was announced on July 18, Zoom shares have lost more than 20% of their value, while Five9 has dipped about 5%.\nA pandemic winner whose shares had surged nearly 396% last year, Zoom struck its largest-ever acquisition for Five9 in a bid to expand beyond its core video-conferencing services.\nThe company earlier this month announced improvements and expansions to its services that included event lobbies, chat, networking in the hope that consumers will continue to use its platform for remote-working.\nHowever, ISS said the new additions failed to assuage shareholder concerns of continued business churn, while Five9's prospects have improved since the acquisition was announced and could attract more bidders if the deal falls apart.\nZoom and Five9 were not immediately available for a comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":601210045,"gmtCreate":1638533688808,"gmtModify":1638533703139,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601210045","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohu8.com/m/news/1144924535?lang=&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p>\n<p>Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p>\n<p>Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873461782,"gmtCreate":1636978021684,"gmtModify":1636978022119,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>Ddd","listText":"<a href=\"https://laohu8.com/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>Ddd","text":"$SINGAPORE EXCHANGE LIMITED(S68.SI)$Ddd","images":[{"img":"https://static.tigerbbs.com/516b780597444df30d5763000807b54b","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/873461782","isVote":1,"tweetType":1,"viewCount":484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861873972,"gmtCreate":1632488121596,"gmtModify":1632718459090,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/861873972","repostId":"1142559059","repostType":4,"repost":{"id":"1142559059","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632484839,"share":"https://www.laohu8.com/m/news/1142559059?lang=&edition=full","pubTime":"2021-09-24 20:00","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1142559059","media":"Tiger Newspress","summary":"(Sept 24) Stock futures gave back gains after equities' best day since July.\nAt 08:01 a.m. ET, Dow e","content":"<p>(Sept 24)&nbsp;Stock futures gave back gains after equities' best day since July.</p>\n<p>At 08:01 a.m. ET, Dow e-minis were down 149 points, or 0.43%, S&amp;P 500 e-minis fell 22.75 points, or 0.51%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis sank 106.5&nbsp;points, or 0.70%.</p>\n<p><img src=\"https://static.tigerbbs.com/30a653559f88adfa0843eba93e9dc775\" tg-width=\"1242\" tg-height=\"493\" referrerpolicy=\"no-referrer\"></p>\n<p>Cryptocurrency-exposed stocks slumped in U.S.&nbsp;premarket&nbsp;trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%.</p>\n<p>Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p>Robinhood(HOOD),Coinbase(COIN) -- Shares of the retail trading app and cryptocurrency exchange fell in premarket trading after China signaled that it was intensifying its crackdown on crypto.The country's central bank said Friday that all cryptocurrency-related activities are illegal. Shares of Coinbase fell more than 3.6% while Robinhood dropped 2%.</p>\n<p>Roku(ROKU) — Shares of the streaming video platform fell in premarket trading afterWells Fargo downgraded Roku to equal weight from overweight. The investment firm said in a note that Wall Street expectations for Roku's revenue growth are likely too high as competition increases. Shares of Roku were down 2.3%.</p>\n<p>Nike(NKE) — The apparel giant’s stock was under pressure on Friday afterNike cut its revenue forecasts due to supply chain issues.The company said it expects full-year sales growth in the mid-single digits for the 2022 fiscal year, down from a previous forecast of low double-digit growth. Shares of Nike fell more than 4% in premarket trading.</p>\n<p>Under Armour(UAA) — The athletic apparel retailer’s stock fell in premarket trading after rival Nike cut its guidance. Shares of Under Armour were down more than 2% in premarket trading.</p>\n<p>Costco(COST) — The retailer beat expectations on the top and bottom lines in its fiscal fourth-quarter report on Thursday afternoon. The company reported $3.90 in adjusted earnings per share, easily topping expectations of $3.57, and net sales for the quarter rose more than 17% year over year. The stock was slightly higher in premarket trading.</p>\n<p>Merck(MRK) — The pharmaceutical giant, along withAstraZeneca, announced on Friday morning that a treatment using the drug Lynparza slowed the progression of prostate cancer in a phase three trial. Shares of Merck rose more than 1% in premarket trading.</p>\n<p>Cheesecake Factory(CAKE),Dave &amp; Buster's(PLAY) — The restaurant stocks rose slightly in premarket trading after Jefferies upgraded the stocks to buy from hold. The firm said that full-service restaurants have seen traffic hold up well despite the spread of the delta variant.</p>\n<p>Helbiz (HLBZ) — Helbiz&nbsp;falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders.</p>\n<p>Focus Universal (FCUV), —&nbsp;Focus Universal&nbsp;an online marketing company that’s been a favorite of retail traders, surged 26% in&nbsp;premarket&nbsp;trading after the stock was cited on Stocktwits in recent days.</p>\n<p>Vail Resorts (MTN) — Vail Resorts&nbsp;falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint.</p>\n<p>GlycoMimetics (GLYC) — GlycoMimetics&nbsp;jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16.</p>\n<p>VTV Therapeutics (VTVT) —&nbsp;VTV Therapeutics&nbsp;surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. </p>\n<p><b>In FX, </b>the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as&nbsp; businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support</p>\n<p><b>In commodities,</b> crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal.</p>\n<p>Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-24 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 24)&nbsp;Stock futures gave back gains after equities' best day since July.</p>\n<p>At 08:01 a.m. ET, Dow e-minis were down 149 points, or 0.43%, S&amp;P 500 e-minis fell 22.75 points, or 0.51%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis sank 106.5&nbsp;points, or 0.70%.</p>\n<p><img src=\"https://static.tigerbbs.com/30a653559f88adfa0843eba93e9dc775\" tg-width=\"1242\" tg-height=\"493\" referrerpolicy=\"no-referrer\"></p>\n<p>Cryptocurrency-exposed stocks slumped in U.S.&nbsp;premarket&nbsp;trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%.</p>\n<p>Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p>Robinhood(HOOD),Coinbase(COIN) -- Shares of the retail trading app and cryptocurrency exchange fell in premarket trading after China signaled that it was intensifying its crackdown on crypto.The country's central bank said Friday that all cryptocurrency-related activities are illegal. Shares of Coinbase fell more than 3.6% while Robinhood dropped 2%.</p>\n<p>Roku(ROKU) — Shares of the streaming video platform fell in premarket trading afterWells Fargo downgraded Roku to equal weight from overweight. The investment firm said in a note that Wall Street expectations for Roku's revenue growth are likely too high as competition increases. Shares of Roku were down 2.3%.</p>\n<p>Nike(NKE) — The apparel giant’s stock was under pressure on Friday afterNike cut its revenue forecasts due to supply chain issues.The company said it expects full-year sales growth in the mid-single digits for the 2022 fiscal year, down from a previous forecast of low double-digit growth. Shares of Nike fell more than 4% in premarket trading.</p>\n<p>Under Armour(UAA) — The athletic apparel retailer’s stock fell in premarket trading after rival Nike cut its guidance. Shares of Under Armour were down more than 2% in premarket trading.</p>\n<p>Costco(COST) — The retailer beat expectations on the top and bottom lines in its fiscal fourth-quarter report on Thursday afternoon. The company reported $3.90 in adjusted earnings per share, easily topping expectations of $3.57, and net sales for the quarter rose more than 17% year over year. The stock was slightly higher in premarket trading.</p>\n<p>Merck(MRK) — The pharmaceutical giant, along withAstraZeneca, announced on Friday morning that a treatment using the drug Lynparza slowed the progression of prostate cancer in a phase three trial. Shares of Merck rose more than 1% in premarket trading.</p>\n<p>Cheesecake Factory(CAKE),Dave &amp; Buster's(PLAY) — The restaurant stocks rose slightly in premarket trading after Jefferies upgraded the stocks to buy from hold. The firm said that full-service restaurants have seen traffic hold up well despite the spread of the delta variant.</p>\n<p>Helbiz (HLBZ) — Helbiz&nbsp;falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders.</p>\n<p>Focus Universal (FCUV), —&nbsp;Focus Universal&nbsp;an online marketing company that’s been a favorite of retail traders, surged 26% in&nbsp;premarket&nbsp;trading after the stock was cited on Stocktwits in recent days.</p>\n<p>Vail Resorts (MTN) — Vail Resorts&nbsp;falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint.</p>\n<p>GlycoMimetics (GLYC) — GlycoMimetics&nbsp;jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16.</p>\n<p>VTV Therapeutics (VTVT) —&nbsp;VTV Therapeutics&nbsp;surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. </p>\n<p><b>In FX, </b>the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as&nbsp; businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support</p>\n<p><b>In commodities,</b> crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal.</p>\n<p>Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142559059","content_text":"(Sept 24) Stock futures gave back gains after equities' best day since July.\nAt 08:01 a.m. ET, Dow e-minis were down 149 points, or 0.43%, S&P 500 e-minis fell 22.75 points, or 0.51%, and Nasdaq 100 e-minis sank 106.5 points, or 0.70%.\n\nCryptocurrency-exposed stocks slumped in U.S. premarket trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%.\nBig banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits.\nStocks making the biggest moves premarket:\nRobinhood(HOOD),Coinbase(COIN) -- Shares of the retail trading app and cryptocurrency exchange fell in premarket trading after China signaled that it was intensifying its crackdown on crypto.The country's central bank said Friday that all cryptocurrency-related activities are illegal. Shares of Coinbase fell more than 3.6% while Robinhood dropped 2%.\nRoku(ROKU) — Shares of the streaming video platform fell in premarket trading afterWells Fargo downgraded Roku to equal weight from overweight. The investment firm said in a note that Wall Street expectations for Roku's revenue growth are likely too high as competition increases. Shares of Roku were down 2.3%.\nNike(NKE) — The apparel giant’s stock was under pressure on Friday afterNike cut its revenue forecasts due to supply chain issues.The company said it expects full-year sales growth in the mid-single digits for the 2022 fiscal year, down from a previous forecast of low double-digit growth. Shares of Nike fell more than 4% in premarket trading.\nUnder Armour(UAA) — The athletic apparel retailer’s stock fell in premarket trading after rival Nike cut its guidance. Shares of Under Armour were down more than 2% in premarket trading.\nCostco(COST) — The retailer beat expectations on the top and bottom lines in its fiscal fourth-quarter report on Thursday afternoon. The company reported $3.90 in adjusted earnings per share, easily topping expectations of $3.57, and net sales for the quarter rose more than 17% year over year. The stock was slightly higher in premarket trading.\nMerck(MRK) — The pharmaceutical giant, along withAstraZeneca, announced on Friday morning that a treatment using the drug Lynparza slowed the progression of prostate cancer in a phase three trial. Shares of Merck rose more than 1% in premarket trading.\nCheesecake Factory(CAKE),Dave & Buster's(PLAY) — The restaurant stocks rose slightly in premarket trading after Jefferies upgraded the stocks to buy from hold. The firm said that full-service restaurants have seen traffic hold up well despite the spread of the delta variant.\nHelbiz (HLBZ) — Helbiz falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders.\nFocus Universal (FCUV), — Focus Universal an online marketing company that’s been a favorite of retail traders, surged 26% in premarket trading after the stock was cited on Stocktwits in recent days.\nVail Resorts (MTN) — Vail Resorts falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint.\nGlycoMimetics (GLYC) — GlycoMimetics jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16.\nVTV Therapeutics (VTVT) — VTV Therapeutics surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. \nIn FX, the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as  businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support\nIn commodities, crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal.\nLooking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan.","news_type":1},"isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889709925,"gmtCreate":1631175361667,"gmtModify":1631883916102,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"All Red ( Red is the colour of luck) 💋💋💋","listText":"All Red ( Red is the colour of luck) 💋💋💋","text":"All Red ( Red is the colour of luck) 💋💋💋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/889709925","repostId":"1176538965","repostType":4,"repost":{"id":"1176538965","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631174811,"share":"https://www.laohu8.com/m/news/1176538965?lang=&edition=full","pubTime":"2021-09-09 16:06","market":"us","language":"en","title":"Most of China concepts stocks fell in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1176538965","media":"Tiger Newspress","summary":"(Sept 9)&nbsp;Most of China concepts stocks fell in premarket trading.","content":"<p>(Sept 9)&nbsp;Most of China concepts stocks fell in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1cc6e1e421893d8bebaea0dc552bf76\" tg-width=\"279\" tg-height=\"728\" width=\"100%\" height=\"auto\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Most of China concepts stocks fell in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMost of China concepts stocks fell in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-09 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 9)&nbsp;Most of China concepts stocks fell in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1cc6e1e421893d8bebaea0dc552bf76\" tg-width=\"279\" tg-height=\"728\" width=\"100%\" height=\"auto\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176538965","content_text":"(Sept 9) Most of China concepts stocks fell in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":57,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815733937,"gmtCreate":1630718368829,"gmtModify":1631891082263,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Thanks ☺️&nbsp;","listText":"Thanks ☺️&nbsp;","text":"Thanks ☺️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815733937","repostId":"2164803577","repostType":4,"repost":{"id":"2164803577","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630699233,"share":"https://www.laohu8.com/m/news/2164803577?lang=&edition=full","pubTime":"2021-09-04 04:00","market":"us","language":"en","title":"Tech lifts Nasdaq to record close but Wall Street mixed on jobs report","url":"https://stock-news.laohu8.com/highlight/detail?id=2164803577","media":"Reuters","summary":"Dismal August jobs report calms taper fears\nLeisure, retail employment disappoint; cruise liners slu","content":"<ul>\n <li>Dismal August jobs report calms taper fears</li>\n <li>Leisure, retail employment disappoint; cruise liners slump</li>\n <li>Banking stocks slide, shrug off jump in bond yields</li>\n</ul>\n<p>Sept 3 (Reuters) - The Nasdaq closed Friday at a fresh record but Wall Street's main indexes headed into the Labor Day weekend in mixed fashion, reacting to a disappointing U.S. jobs report which raised fears about the pace of economic recovery but weakened the argument for near-term tapering.</p>\n<p>A majority of the 11 S&amp;P sectors ended lower, with the energy and financial indexes among those finishing in the red.</p>\n<p>Banking stocks, which generally perform better when bond yields are higher, dropped even as the benchmark 10-year Treasury yield jumped following the report.</p>\n<p>\"The number's a big disappointment and it's clear the Delta variant had a negative impact on the labor economy this summer,\" said Michael Arone, chief investment strategist at State Street Global Advisors in Boston.</p>\n<p>\"You can tell because leisure and hospitality didn't add any jobs and retail actually lost jobs. Investors will conclude that perhaps this will put the (Federal Reserve) further on hold in terms of the timing of tapering. Markets may be okay with that.\"</p>\n<p>Among the biggest decliners on the S&amp;P 500 were cruise ship operators, including Norwegian Cruise Line Holdings , Carnival Corp and Royal Caribbean Cruises , whose businesses are highly susceptible to consumer sentiment around travel and COVID-19.</p>\n<p>The S&amp;P 500 and the Nasdaq had scaled all-time highs over the past few weeks on support from robust corporate earnings, but investors have remained generally cautious as they watch economic indicators and the jump in U.S. infections to see how that might influence the Fed and its tapering plans.</p>\n<p>The labor market remains the key touchstone for the Fed, with Chair Jerome Powell hinting last week that reaching full employment was a pre-requisite for the central bank to start paring back its asset purchases.</p>\n<p>On Friday, the Labor Department's closely watched report showed nonfarm payrolls increased by 235,000 jobs in August, widely missing economists' estimate of 750,000. Payrolls had surged 1.05 million in July.</p>\n<p>Despite a number well outside the consensus estimate, the overall reaction of investors was muted, continuing a trend over the last year of a decoupling of significant S&amp;P movement in the wake of a wide miss on the payrolls report.</p>\n<p>Unofficially, the Dow Jones Industrial Average fell 74.47 points, or 0.21%, to 35,369.35, the S&amp;P 500 lost 1.41 points, or 0.03%, to 4,535.54 and the Nasdaq Composite&nbsp;added 32.34 points, or 0.21%, to 15,363.52.</p>\n<p>The Nasdaq, registering a fifth daily gain in the last six sessions, was boosted by technology heavyweights, including Apple , Alphabet , and <a href=\"https://laohu8.com/S/FB\">Facebook</a>. Tech stocks tend to perform better in a low interest-rate environment.</p>\n<p>Chinese ride-hailing firm Didi Global gained after a media report that the city of Beijing was considering moves that would give state entities control of the company.</p>\n<p>Biotechnology firm Forte Biosciences slumped after its experimental treatment for eczema, a skin disease, failed to meet its main goal.</p>\n<p>(Reporting by Shashank Nayar in Bengaluru and Stephen Culp and David French in New York; Editing by Arun Koyyur and Marguerita Choy)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech lifts Nasdaq to record close but Wall Street mixed on jobs report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech lifts Nasdaq to record close but Wall Street mixed on jobs report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-04 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Dismal August jobs report calms taper fears</li>\n <li>Leisure, retail employment disappoint; cruise liners slump</li>\n <li>Banking stocks slide, shrug off jump in bond yields</li>\n</ul>\n<p>Sept 3 (Reuters) - The Nasdaq closed Friday at a fresh record but Wall Street's main indexes headed into the Labor Day weekend in mixed fashion, reacting to a disappointing U.S. jobs report which raised fears about the pace of economic recovery but weakened the argument for near-term tapering.</p>\n<p>A majority of the 11 S&amp;P sectors ended lower, with the energy and financial indexes among those finishing in the red.</p>\n<p>Banking stocks, which generally perform better when bond yields are higher, dropped even as the benchmark 10-year Treasury yield jumped following the report.</p>\n<p>\"The number's a big disappointment and it's clear the Delta variant had a negative impact on the labor economy this summer,\" said Michael Arone, chief investment strategist at State Street Global Advisors in Boston.</p>\n<p>\"You can tell because leisure and hospitality didn't add any jobs and retail actually lost jobs. Investors will conclude that perhaps this will put the (Federal Reserve) further on hold in terms of the timing of tapering. Markets may be okay with that.\"</p>\n<p>Among the biggest decliners on the S&amp;P 500 were cruise ship operators, including Norwegian Cruise Line Holdings , Carnival Corp and Royal Caribbean Cruises , whose businesses are highly susceptible to consumer sentiment around travel and COVID-19.</p>\n<p>The S&amp;P 500 and the Nasdaq had scaled all-time highs over the past few weeks on support from robust corporate earnings, but investors have remained generally cautious as they watch economic indicators and the jump in U.S. infections to see how that might influence the Fed and its tapering plans.</p>\n<p>The labor market remains the key touchstone for the Fed, with Chair Jerome Powell hinting last week that reaching full employment was a pre-requisite for the central bank to start paring back its asset purchases.</p>\n<p>On Friday, the Labor Department's closely watched report showed nonfarm payrolls increased by 235,000 jobs in August, widely missing economists' estimate of 750,000. Payrolls had surged 1.05 million in July.</p>\n<p>Despite a number well outside the consensus estimate, the overall reaction of investors was muted, continuing a trend over the last year of a decoupling of significant S&amp;P movement in the wake of a wide miss on the payrolls report.</p>\n<p>Unofficially, the Dow Jones Industrial Average fell 74.47 points, or 0.21%, to 35,369.35, the S&amp;P 500 lost 1.41 points, or 0.03%, to 4,535.54 and the Nasdaq Composite&nbsp;added 32.34 points, or 0.21%, to 15,363.52.</p>\n<p>The Nasdaq, registering a fifth daily gain in the last six sessions, was boosted by technology heavyweights, including Apple , Alphabet , and <a href=\"https://laohu8.com/S/FB\">Facebook</a>. Tech stocks tend to perform better in a low interest-rate environment.</p>\n<p>Chinese ride-hailing firm Didi Global gained after a media report that the city of Beijing was considering moves that would give state entities control of the company.</p>\n<p>Biotechnology firm Forte Biosciences slumped after its experimental treatment for eczema, a skin disease, failed to meet its main goal.</p>\n<p>(Reporting by Shashank Nayar in Bengaluru and Stephen Culp and David French in New York; Editing by Arun Koyyur and Marguerita Choy)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164803577","content_text":"Dismal August jobs report calms taper fears\nLeisure, retail employment disappoint; cruise liners slump\nBanking stocks slide, shrug off jump in bond yields\n\nSept 3 (Reuters) - The Nasdaq closed Friday at a fresh record but Wall Street's main indexes headed into the Labor Day weekend in mixed fashion, reacting to a disappointing U.S. jobs report which raised fears about the pace of economic recovery but weakened the argument for near-term tapering.\nA majority of the 11 S&P sectors ended lower, with the energy and financial indexes among those finishing in the red.\nBanking stocks, which generally perform better when bond yields are higher, dropped even as the benchmark 10-year Treasury yield jumped following the report.\n\"The number's a big disappointment and it's clear the Delta variant had a negative impact on the labor economy this summer,\" said Michael Arone, chief investment strategist at State Street Global Advisors in Boston.\n\"You can tell because leisure and hospitality didn't add any jobs and retail actually lost jobs. Investors will conclude that perhaps this will put the (Federal Reserve) further on hold in terms of the timing of tapering. Markets may be okay with that.\"\nAmong the biggest decliners on the S&P 500 were cruise ship operators, including Norwegian Cruise Line Holdings , Carnival Corp and Royal Caribbean Cruises , whose businesses are highly susceptible to consumer sentiment around travel and COVID-19.\nThe S&P 500 and the Nasdaq had scaled all-time highs over the past few weeks on support from robust corporate earnings, but investors have remained generally cautious as they watch economic indicators and the jump in U.S. infections to see how that might influence the Fed and its tapering plans.\nThe labor market remains the key touchstone for the Fed, with Chair Jerome Powell hinting last week that reaching full employment was a pre-requisite for the central bank to start paring back its asset purchases.\nOn Friday, the Labor Department's closely watched report showed nonfarm payrolls increased by 235,000 jobs in August, widely missing economists' estimate of 750,000. Payrolls had surged 1.05 million in July.\nDespite a number well outside the consensus estimate, the overall reaction of investors was muted, continuing a trend over the last year of a decoupling of significant S&P movement in the wake of a wide miss on the payrolls report.\nUnofficially, the Dow Jones Industrial Average fell 74.47 points, or 0.21%, to 35,369.35, the S&P 500 lost 1.41 points, or 0.03%, to 4,535.54 and the Nasdaq Composite added 32.34 points, or 0.21%, to 15,363.52.\nThe Nasdaq, registering a fifth daily gain in the last six sessions, was boosted by technology heavyweights, including Apple , Alphabet , and Facebook. Tech stocks tend to perform better in a low interest-rate environment.\nChinese ride-hailing firm Didi Global gained after a media report that the city of Beijing was considering moves that would give state entities control of the company.\nBiotechnology firm Forte Biosciences slumped after its experimental treatment for eczema, a skin disease, failed to meet its main goal.\n(Reporting by Shashank Nayar in Bengaluru and Stephen Culp and David French in New York; Editing by Arun Koyyur and Marguerita Choy)","news_type":1},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811277246,"gmtCreate":1630330605185,"gmtModify":1704958550263,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/811277246","repostId":"1182616475","repostType":4,"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894762692,"gmtCreate":1628858205516,"gmtModify":1633688968611,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894762692","repostId":"1137098889","repostType":4,"repost":{"id":"1137098889","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628856721,"share":"https://www.laohu8.com/m/news/1137098889?lang=&edition=full","pubTime":"2021-08-13 20:12","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1137098889","media":"Tiger Newspress","summary":"The Dow and the S&P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beatin","content":"<p>The Dow and the S&amp;P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beating results, while signs of cooling inflation and a strong recovery in corporate earnings kept the indexes on track for a second straight week of gains.</p>\n<p>At 8:10 a.m. ET, Dow E-minis were up 59 points, or 0.17%, S&amp;P 500 E-minis were up 1.5 points, or 0.03% and Nasdaq 100 E-minis were down 17 points, or 0.11%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f7c31d72fc86500c83b0502d21899072\" tg-width=\"1172\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>A stellar earnings season, improving economic data and the Senate’s passage of a large infrastructure bill have all reinforced investors’ belief in the economic recovery, pushing U.S. stocks to all-time highs in the past few sessions.</p>\n<p>Concerns over higher inflation and a sooner-than-anticipated policy tapering by the Federal Reserve also ebbed after data earlier this week showed the pace of increase in U.S. consumer prices slowed in July even as producer prices posted their biggest annual increase in more than a decade.</p>\n<p>Investors now await the minutes of the Fed’s latest policy meeting, due next week, and the annual meeting of central bankers in Jackson Hole, Wyoming, later in August for policy cues.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/DIS\">Walt Disney</a> – Walt Disney reported adjusted quarterly earnings of 80 cents per share, well above the 55-cent consensus estimate, with revenue beating forecasts as well. Disney’s performance was boosted by a rebound in U.S. theme park attendance as well as stronger-than-expected growth for its Disney+ streaming service. The company did, however, warn of uncertainty surrounding the impact of the delta coronavirus variant. Disney shares rallied 5.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a> – Airbnb lost 11 cents per share for its latest quarter, smaller than the 47-cent loss that analysts were anticipating. Revenue exceeded estimates, nearly quadrupling from a year earlier as domestic travel rebounded from its pandemic lows. However, the company pointed to uncertainty surrounding the pandemic and the delta variant, and Airbnb shares slid 2.8% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/ME\">23andMe, Inc.</a> – The genetic research company reported revenue of $59 million in its first quarter as a public company, up 23% from a year ago, while reporting a smaller loss. 23andMe shares climbed 2.1% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash posted a quarterly loss of 30 cents per share, wider than the 20 cents that Wall Street had projected. However, the food delivery service’s revenue did beat estimates, with gross order volume up 70% from a year ago. DoorDash also raised its full-year guidance for gross order volume. DoorDash shares fell 4.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies Inc.</a> – SoFi lost 48 cents per share for its second quarter, compared with analyst forecasts of a 6 cents per share loss. The digital financial services company’s revenue exceeded estimates, as membership more than doubled from a year earlier, but the stock tanked 9.6% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> ,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> ,<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> – The FDA authorized Covid-19 vaccine booster shots for immunocompromised people utilizing the Pfizer/BioNTech and Moderna vaccines. Pfizer added 0.2%, BioNTech climbed 2.4% and Moderna gained 2.3%.</p>\n<p><a href=\"https://laohu8.com/S/ERJ\">Embraer SA</a> – The Brazilian jet maker posted its first recurring quarterly profit since the first quarter of 2018, as travel demand rebounded from the lowest levels of the pandemic. Shares jumped 3.6% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KSU\">Kansas City Southern</a> – Kansas City Southern rejected an improved takeover offer fromCanadian Pacific Railway(CP), saying it did not constitute a “superior proposal” to its agreement withCanadian National Railway(CNI). The Canadian Pacific offer is worth $27 billion compared to $29 billion for Canadian National, but Canadian Pacific feels its bid has a better chance of regulatory approval.</p>\n<p><a href=\"https://laohu8.com/S/ZIP\">ZipRecruiter Inc.</a> – ZipRecruiter posted a quarterly loss of 55 cents per share, compared with a consensus estimate of a 22 cents per share loss. However, the online employment marketplace operator saw revenue well above Street forecasts and made upbeat comments about the remainder of 2021. ZipRecruiter surged 14.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a> – Rocket shares gained 5.4% in premarket action despite a miss on the top and bottom lines for the online mortgage platform operator. Rocket did see a surge in closed loan origination volume over a year ago and gave upbeat current-quarter guidance for a variety of metrics.</p>\n<p><a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a> – The e-commerce platform company’s stock tumbled 27.8% in the premarket, following top and bottom line misses for its latest quarter. The operator of wish.com said it saw slowing demand for its products, fewer users and active buyers, and higher costs.</p>\n<p><a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> – The videogame maker’s stock added 1.1% in premarket trading after Citi upgraded it to “buy” from “neutral”, saying the current risk/reward profile looks favorable following the stock’s recent pullback.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Dow and the S&amp;P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beating results, while signs of cooling inflation and a strong recovery in corporate earnings kept the indexes on track for a second straight week of gains.</p>\n<p>At 8:10 a.m. ET, Dow E-minis were up 59 points, or 0.17%, S&amp;P 500 E-minis were up 1.5 points, or 0.03% and Nasdaq 100 E-minis were down 17 points, or 0.11%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f7c31d72fc86500c83b0502d21899072\" tg-width=\"1172\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>A stellar earnings season, improving economic data and the Senate’s passage of a large infrastructure bill have all reinforced investors’ belief in the economic recovery, pushing U.S. stocks to all-time highs in the past few sessions.</p>\n<p>Concerns over higher inflation and a sooner-than-anticipated policy tapering by the Federal Reserve also ebbed after data earlier this week showed the pace of increase in U.S. consumer prices slowed in July even as producer prices posted their biggest annual increase in more than a decade.</p>\n<p>Investors now await the minutes of the Fed’s latest policy meeting, due next week, and the annual meeting of central bankers in Jackson Hole, Wyoming, later in August for policy cues.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/DIS\">Walt Disney</a> – Walt Disney reported adjusted quarterly earnings of 80 cents per share, well above the 55-cent consensus estimate, with revenue beating forecasts as well. Disney’s performance was boosted by a rebound in U.S. theme park attendance as well as stronger-than-expected growth for its Disney+ streaming service. The company did, however, warn of uncertainty surrounding the impact of the delta coronavirus variant. Disney shares rallied 5.5% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a> – Airbnb lost 11 cents per share for its latest quarter, smaller than the 47-cent loss that analysts were anticipating. Revenue exceeded estimates, nearly quadrupling from a year earlier as domestic travel rebounded from its pandemic lows. However, the company pointed to uncertainty surrounding the pandemic and the delta variant, and Airbnb shares slid 2.8% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/ME\">23andMe, Inc.</a> – The genetic research company reported revenue of $59 million in its first quarter as a public company, up 23% from a year ago, while reporting a smaller loss. 23andMe shares climbed 2.1% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash posted a quarterly loss of 30 cents per share, wider than the 20 cents that Wall Street had projected. However, the food delivery service’s revenue did beat estimates, with gross order volume up 70% from a year ago. DoorDash also raised its full-year guidance for gross order volume. DoorDash shares fell 4.2% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies Inc.</a> – SoFi lost 48 cents per share for its second quarter, compared with analyst forecasts of a 6 cents per share loss. The digital financial services company’s revenue exceeded estimates, as membership more than doubled from a year earlier, but the stock tanked 9.6% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> ,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> ,<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> – The FDA authorized Covid-19 vaccine booster shots for immunocompromised people utilizing the Pfizer/BioNTech and Moderna vaccines. Pfizer added 0.2%, BioNTech climbed 2.4% and Moderna gained 2.3%.</p>\n<p><a href=\"https://laohu8.com/S/ERJ\">Embraer SA</a> – The Brazilian jet maker posted its first recurring quarterly profit since the first quarter of 2018, as travel demand rebounded from the lowest levels of the pandemic. Shares jumped 3.6% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/KSU\">Kansas City Southern</a> – Kansas City Southern rejected an improved takeover offer fromCanadian Pacific Railway(CP), saying it did not constitute a “superior proposal” to its agreement withCanadian National Railway(CNI). The Canadian Pacific offer is worth $27 billion compared to $29 billion for Canadian National, but Canadian Pacific feels its bid has a better chance of regulatory approval.</p>\n<p><a href=\"https://laohu8.com/S/ZIP\">ZipRecruiter Inc.</a> – ZipRecruiter posted a quarterly loss of 55 cents per share, compared with a consensus estimate of a 22 cents per share loss. However, the online employment marketplace operator saw revenue well above Street forecasts and made upbeat comments about the remainder of 2021. ZipRecruiter surged 14.3% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a> – Rocket shares gained 5.4% in premarket action despite a miss on the top and bottom lines for the online mortgage platform operator. Rocket did see a surge in closed loan origination volume over a year ago and gave upbeat current-quarter guidance for a variety of metrics.</p>\n<p><a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a> – The e-commerce platform company’s stock tumbled 27.8% in the premarket, following top and bottom line misses for its latest quarter. The operator of wish.com said it saw slowing demand for its products, fewer users and active buyers, and higher costs.</p>\n<p><a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> – The videogame maker’s stock added 1.1% in premarket trading after Citi upgraded it to “buy” from “neutral”, saying the current risk/reward profile looks favorable following the stock’s recent pullback.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137098889","content_text":"The Dow and the S&P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beating results, while signs of cooling inflation and a strong recovery in corporate earnings kept the indexes on track for a second straight week of gains.\nAt 8:10 a.m. ET, Dow E-minis were up 59 points, or 0.17%, S&P 500 E-minis were up 1.5 points, or 0.03% and Nasdaq 100 E-minis were down 17 points, or 0.11%.\n*Source From Tiger Trade, EST 08:10\nA stellar earnings season, improving economic data and the Senate’s passage of a large infrastructure bill have all reinforced investors’ belief in the economic recovery, pushing U.S. stocks to all-time highs in the past few sessions.\nConcerns over higher inflation and a sooner-than-anticipated policy tapering by the Federal Reserve also ebbed after data earlier this week showed the pace of increase in U.S. consumer prices slowed in July even as producer prices posted their biggest annual increase in more than a decade.\nInvestors now await the minutes of the Fed’s latest policy meeting, due next week, and the annual meeting of central bankers in Jackson Hole, Wyoming, later in August for policy cues.\nStocks making the biggest moves in the premarket:\nWalt Disney – Walt Disney reported adjusted quarterly earnings of 80 cents per share, well above the 55-cent consensus estimate, with revenue beating forecasts as well. Disney’s performance was boosted by a rebound in U.S. theme park attendance as well as stronger-than-expected growth for its Disney+ streaming service. The company did, however, warn of uncertainty surrounding the impact of the delta coronavirus variant. Disney shares rallied 5.5% in the premarket.\nAirbnb, Inc. – Airbnb lost 11 cents per share for its latest quarter, smaller than the 47-cent loss that analysts were anticipating. Revenue exceeded estimates, nearly quadrupling from a year earlier as domestic travel rebounded from its pandemic lows. However, the company pointed to uncertainty surrounding the pandemic and the delta variant, and Airbnb shares slid 2.8% in premarket trading.\n23andMe, Inc. – The genetic research company reported revenue of $59 million in its first quarter as a public company, up 23% from a year ago, while reporting a smaller loss. 23andMe shares climbed 2.1% in premarket action.\nDoorDash, Inc. – DoorDash posted a quarterly loss of 30 cents per share, wider than the 20 cents that Wall Street had projected. However, the food delivery service’s revenue did beat estimates, with gross order volume up 70% from a year ago. DoorDash also raised its full-year guidance for gross order volume. DoorDash shares fell 4.2% in the premarket.\nSoFi Technologies Inc. – SoFi lost 48 cents per share for its second quarter, compared with analyst forecasts of a 6 cents per share loss. The digital financial services company’s revenue exceeded estimates, as membership more than doubled from a year earlier, but the stock tanked 9.6% in premarket action.\nPfizer ,BioNTech SE ,Moderna, Inc. – The FDA authorized Covid-19 vaccine booster shots for immunocompromised people utilizing the Pfizer/BioNTech and Moderna vaccines. Pfizer added 0.2%, BioNTech climbed 2.4% and Moderna gained 2.3%.\nEmbraer SA – The Brazilian jet maker posted its first recurring quarterly profit since the first quarter of 2018, as travel demand rebounded from the lowest levels of the pandemic. Shares jumped 3.6% in the premarket.\nKansas City Southern – Kansas City Southern rejected an improved takeover offer fromCanadian Pacific Railway(CP), saying it did not constitute a “superior proposal” to its agreement withCanadian National Railway(CNI). The Canadian Pacific offer is worth $27 billion compared to $29 billion for Canadian National, but Canadian Pacific feels its bid has a better chance of regulatory approval.\nZipRecruiter Inc. – ZipRecruiter posted a quarterly loss of 55 cents per share, compared with a consensus estimate of a 22 cents per share loss. However, the online employment marketplace operator saw revenue well above Street forecasts and made upbeat comments about the remainder of 2021. ZipRecruiter surged 14.3% in the premarket.\nRocket Companies – Rocket shares gained 5.4% in premarket action despite a miss on the top and bottom lines for the online mortgage platform operator. Rocket did see a surge in closed loan origination volume over a year ago and gave upbeat current-quarter guidance for a variety of metrics.\nContextLogic Inc. – The e-commerce platform company’s stock tumbled 27.8% in the premarket, following top and bottom line misses for its latest quarter. The operator of wish.com said it saw slowing demand for its products, fewer users and active buyers, and higher costs.\nActivision Blizzard – The videogame maker’s stock added 1.1% in premarket trading after Citi upgraded it to “buy” from “neutral”, saying the current risk/reward profile looks favorable following the stock’s recent pullback.","news_type":1},"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895130647,"gmtCreate":1628727637589,"gmtModify":1633744827143,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Need support to more online 😬","listText":"Need support to more online 😬","text":"Need support to more online 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/895130647","repostId":"2158845236","repostType":4,"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895379887,"gmtCreate":1628726562249,"gmtModify":1633744854964,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Friday sleep 💤&nbsp;","listText":"Friday sleep 💤&nbsp;","text":"Friday sleep 💤","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/895379887","repostId":"1146833505","repostType":4,"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891420249,"gmtCreate":1628413918381,"gmtModify":1633747249108,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Gotta&nbsp;","listText":"Gotta&nbsp;","text":"Gotta","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891420249","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohu8.com/m/news/1180529438?lang=&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.</p>\n<p><b>What Happened:</b>&nbsp;According to a Friday SEC&nbsp;announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.</p>\n<p>The SEC notes that Blockchain Credit Partners&nbsp;founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial&nbsp;the accusations.</p>\n<p><b>New Game, Old Rules?</b></p>\n<p>SEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.</p>\n<p>The SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.</p>\n<p>In a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.</p>\n<p><b>What's Next:</b>If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force&nbsp;<b>Ethereum's</b>&nbsp;(CRYPTO: ETH) core development team to write an update stopping such a project?</p>\n<p>If the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away&nbsp;between their fingers like sand, and they are going to try to grab it.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-08 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":605854787,"gmtCreate":1639147765076,"gmtModify":1639147766866,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Down&nbsp;","listText":"Down&nbsp;","text":"Down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605854787","repostId":"1148141788","repostType":4,"repost":{"id":"1148141788","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639147224,"share":"https://www.laohu8.com/m/news/1148141788?lang=&edition=full","pubTime":"2021-12-10 22:40","market":"us","language":"en","title":"Vaccine stocks dropped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148141788","media":"Tiger Newspress","summary":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","content":"<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks dropped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks dropped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148141788","content_text":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603173105,"gmtCreate":1638382301257,"gmtModify":1638382302879,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Ja&nbsp;","listText":"Ja&nbsp;","text":"Ja","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603173105","repostId":"1167889898","repostType":4,"repost":{"id":"1167889898","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638372370,"share":"https://www.laohu8.com/m/news/1167889898?lang=&edition=full","pubTime":"2021-12-01 23:26","market":"us","language":"en","title":"Social media stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1167889898","media":"Tiger Newspress","summary":"Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble climbed between 3% and 6%.\n\n","content":"<p>Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble&nbsp;climbed between 3% and 6%.</p>\n<p><img src=\"https://static.tigerbbs.com/43d7ed750f9c250d3c0ae426133e8935\" tg-width=\"400\" tg-height=\"305\" referrerpolicy=\"no-referrer\"></p>\n<p>Cathie Wood's ARK Investment Management bought more than a million shares of&nbsp;Twitter&nbsp;Inc, a day after Jack Dorsey stepped down as the chief executive of the social networking site;</p>\n<p>Match Group to pay over $400 million to settle Tinder valuation case.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Social media stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSocial media stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble&nbsp;climbed between 3% and 6%.</p>\n<p><img src=\"https://static.tigerbbs.com/43d7ed750f9c250d3c0ae426133e8935\" tg-width=\"400\" tg-height=\"305\" referrerpolicy=\"no-referrer\"></p>\n<p>Cathie Wood's ARK Investment Management bought more than a million shares of&nbsp;Twitter&nbsp;Inc, a day after Jack Dorsey stepped down as the chief executive of the social networking site;</p>\n<p>Match Group to pay over $400 million to settle Tinder valuation case.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMBL":"Bumble Inc.","MTCH":"Match Group, Inc.","PINS":"Pinterest, Inc.","SNAP":"Snap Inc","TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167889898","content_text":"Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble climbed between 3% and 6%.\n\nCathie Wood's ARK Investment Management bought more than a million shares of Twitter Inc, a day after Jack Dorsey stepped down as the chief executive of the social networking site;\nMatch Group to pay over $400 million to settle Tinder valuation case.","news_type":1},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877066485,"gmtCreate":1637844922961,"gmtModify":1637844923386,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877066485","repostId":"2185354679","repostType":4,"repost":{"id":"2185354679","kind":"highlight","pubTimestamp":1637831760,"share":"https://www.laohu8.com/m/news/2185354679?lang=&edition=full","pubTime":"2021-11-25 17:16","market":"us","language":"en","title":"3 Unstoppable Stocks You Can Buy Right Now for Less Than $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2185354679","media":"Motley Fool","summary":"Do you like high growth at an introductory rate? Check out these three stocks.","content":"<p>Many investors get into trading stocks with the desire to find top stocks to buy into early in their growth cycle. That's not so easy to do these days when many stocks get hyped before they even reach the open markets and end up trading at high prices by the time you feel comfortable adding them to your portfolio.</p>\n<p>Still, there are occasional hidden gems in the market that are quietly gaining in growth and recognition, with shares still trading at relatively low prices. <b>Global-e Online</b> (NASDAQ:GLBE),&nbsp;<b>Revolve Group</b> (NYSE:RVLV), and <b><a href=\"https://laohu8.com/S/OPAD\">Offerpad Solutions</a></b>&nbsp;(NYSE:OPAD) are three stocks trading below $100 a share that are demonstrating show-stopping growth. Let's find out a bit more about them.</p>\n<h2>1. Global-e Online: It's a small world after all</h2>\n<p>Global-e Online offers cross-border payment solutions for online retailers. As more and more e-commerce companies expand into new markets and begin to offer international shipping, they begin to discover that there are challenges to making the process cost-effective and worth the investment.</p>\n<p>Global-e comes in to make the process easy, offering features that efficiently manage shipping options, local currencies, calculating customs, and international returns. It has two programs, <a href=\"https://laohu8.com/S/AONE.U\">one</a> for small businesses and one for larger-volume clients, as well as a program with <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a></b> (formerly Facebook) to assist the thousands of sellers using Facebook Marketplace.</p>\n<p>It works with some of the biggest online retailers in the world, including the biggest, French luxury conglomerate <b>LVMH</b>, as well as brands like cosmetic-giant Sephora Asia and French fashion house Givenchy. It also has strong exposure from its partnership with e-commerce master <b>Shopify</b>, through which it powers international commerce with many small and medium-sized brands operating through Shopify services.</p>\n<p>The company is ramping up its operations exponentially. In the third quarter, gross merchandise volume (GMV) grew 86% year over year to a record $352 million, and revenue increased 77% to a record $59 million. That was particularly impressive as e-commerce has begun to modulate after COVID-19 restrictions eased. Gross profit grew 127% year over year to $2 million, although Globel-e posted a $28.5 million loss after a $1.2 million profit last year. Much of the loss was related to increased expenses of scaling up operations specifically related to its Shopify integration.</p>\n<p>Global-e stock went public in May at $25 a share and is up 111% since then. It's not exactly cheap, trading at 43 times trailing-12-month sales, but shares cost $53 as of this writing. It's still a tiny company, with just over $200 million in trailing-12-month earnings. Investors can expect a lot from this high-growth company in the future.</p>\n<h2>2. Revolve Group: Not your typical fashion company</h2>\n<p>At first glance, Revolve Group's website doesn't look different than most other fashion-forward websites. But there's a reason this online fashion retailer that focuses on selling dresses and other apparel for social events is growing by leaps and bounds. That reason involves the underlying infrastructure that's supporting the company's operations. That infrastructure includes 18 years' worth of data supplying its technology-backed artificial intelligence, a modern approach to e-commerce that includes partnerships with influencers and thousands of brands that appeal to its Gen X target consumer.</p>\n<p>Third-quarter sales increased 62% year over year to $244 million, an acceleration from the second quarter. Net income decreased 14% year over year as the company scales, but posting a profit is a great sign from a growth company.</p>\n<p>International sales made up 19% of the total, which is an unusually high number. Its technology supports international sales, and that opens up its addressable market.</p>\n<p>Revolve Group stock is up 160% year to date and shares trade at 66 times trailing-12-month earnings at a current price of $81 a share. But that price won't last long as investors scoop up shares of this high-growth stock.</p>\n<h2>3. Offerpad: Chasing a $1.9 trillion market opportunity</h2>\n<p>Offerpad wants to buy your house for cash before you list it with a Realtor. Then it wants to renovate and flip it, making money in the process. It's a model called ibuying and it's becoming more popular and may soon become the standard in the U.S. real estate market.</p>\n<p>The company's management sees a massive $1.9 trillion opportunity in the housing market, of which only 1% is now online. It has a $1 trillion market in what it calls the \"buy box today\" market, which are U.S. homes for sale that cost up to $750,000.</p>\n<p>Many readers know that <b><a href=\"https://laohu8.com/S/Z\">Zillow</a> Group</b>&nbsp;just bowed out of this market, but it's not clear that there's something wrong with the market or just something wrong with Zillow's ibuying operations. Competitors like Offerpad and <b>Opendoor Technologies</b>&nbsp;are posting high growth, and while investors should do their own research, they shouldn't be scared off from the industry.</p>\n<p>In the third quarter, Offerpad revenue increased 190% year over year to $540 million, and gross profit increased 160% to $53 million. The company sold 1,673 homes, or more than double year over year, and raised its outlook to a midpoint of $1.88 billion in total 2021 sales. Net loss for the quarter expanded from $3 million in 2020 to $15 million in 2021.</p>\n<p>Offerpad stock went public almost a year ago, and shares are down 34.5% year to date, trading around $7.20 a share as of this writing. There's risk involved in investing in this company since it deals with a capital-intensive model, losses are widening, and ibuying hasn't been proven to be a secure business yet. But at this price and with its current growth rates, Offerpad might be a stock to consider for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks You Can Buy Right Now for Less Than $100</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks You Can Buy Right Now for Less Than $100\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/24/3-unstoppable-stocks-can-buy-for-less-that-100/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Many investors get into trading stocks with the desire to find top stocks to buy into early in their growth cycle. That's not so easy to do these days when many stocks get hyped before they even reach...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/24/3-unstoppable-stocks-can-buy-for-less-that-100/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","RVLV":"Revolve Group, LLC","OPAD":"Offerpad Solutions","GLBE":"Global-E Online Ltd.","BK4539":"次新股"},"source_url":"https://www.fool.com/investing/2021/11/24/3-unstoppable-stocks-can-buy-for-less-that-100/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185354679","content_text":"Many investors get into trading stocks with the desire to find top stocks to buy into early in their growth cycle. That's not so easy to do these days when many stocks get hyped before they even reach the open markets and end up trading at high prices by the time you feel comfortable adding them to your portfolio.\nStill, there are occasional hidden gems in the market that are quietly gaining in growth and recognition, with shares still trading at relatively low prices. Global-e Online (NASDAQ:GLBE), Revolve Group (NYSE:RVLV), and Offerpad Solutions (NYSE:OPAD) are three stocks trading below $100 a share that are demonstrating show-stopping growth. Let's find out a bit more about them.\n1. Global-e Online: It's a small world after all\nGlobal-e Online offers cross-border payment solutions for online retailers. As more and more e-commerce companies expand into new markets and begin to offer international shipping, they begin to discover that there are challenges to making the process cost-effective and worth the investment.\nGlobal-e comes in to make the process easy, offering features that efficiently manage shipping options, local currencies, calculating customs, and international returns. It has two programs, one for small businesses and one for larger-volume clients, as well as a program with Meta Platforms (formerly Facebook) to assist the thousands of sellers using Facebook Marketplace.\nIt works with some of the biggest online retailers in the world, including the biggest, French luxury conglomerate LVMH, as well as brands like cosmetic-giant Sephora Asia and French fashion house Givenchy. It also has strong exposure from its partnership with e-commerce master Shopify, through which it powers international commerce with many small and medium-sized brands operating through Shopify services.\nThe company is ramping up its operations exponentially. In the third quarter, gross merchandise volume (GMV) grew 86% year over year to a record $352 million, and revenue increased 77% to a record $59 million. That was particularly impressive as e-commerce has begun to modulate after COVID-19 restrictions eased. Gross profit grew 127% year over year to $2 million, although Globel-e posted a $28.5 million loss after a $1.2 million profit last year. Much of the loss was related to increased expenses of scaling up operations specifically related to its Shopify integration.\nGlobal-e stock went public in May at $25 a share and is up 111% since then. It's not exactly cheap, trading at 43 times trailing-12-month sales, but shares cost $53 as of this writing. It's still a tiny company, with just over $200 million in trailing-12-month earnings. Investors can expect a lot from this high-growth company in the future.\n2. Revolve Group: Not your typical fashion company\nAt first glance, Revolve Group's website doesn't look different than most other fashion-forward websites. But there's a reason this online fashion retailer that focuses on selling dresses and other apparel for social events is growing by leaps and bounds. That reason involves the underlying infrastructure that's supporting the company's operations. That infrastructure includes 18 years' worth of data supplying its technology-backed artificial intelligence, a modern approach to e-commerce that includes partnerships with influencers and thousands of brands that appeal to its Gen X target consumer.\nThird-quarter sales increased 62% year over year to $244 million, an acceleration from the second quarter. Net income decreased 14% year over year as the company scales, but posting a profit is a great sign from a growth company.\nInternational sales made up 19% of the total, which is an unusually high number. Its technology supports international sales, and that opens up its addressable market.\nRevolve Group stock is up 160% year to date and shares trade at 66 times trailing-12-month earnings at a current price of $81 a share. But that price won't last long as investors scoop up shares of this high-growth stock.\n3. Offerpad: Chasing a $1.9 trillion market opportunity\nOfferpad wants to buy your house for cash before you list it with a Realtor. Then it wants to renovate and flip it, making money in the process. It's a model called ibuying and it's becoming more popular and may soon become the standard in the U.S. real estate market.\nThe company's management sees a massive $1.9 trillion opportunity in the housing market, of which only 1% is now online. It has a $1 trillion market in what it calls the \"buy box today\" market, which are U.S. homes for sale that cost up to $750,000.\nMany readers know that Zillow Group just bowed out of this market, but it's not clear that there's something wrong with the market or just something wrong with Zillow's ibuying operations. Competitors like Offerpad and Opendoor Technologies are posting high growth, and while investors should do their own research, they shouldn't be scared off from the industry.\nIn the third quarter, Offerpad revenue increased 190% year over year to $540 million, and gross profit increased 160% to $53 million. The company sold 1,673 homes, or more than double year over year, and raised its outlook to a midpoint of $1.88 billion in total 2021 sales. Net loss for the quarter expanded from $3 million in 2020 to $15 million in 2021.\nOfferpad stock went public almost a year ago, and shares are down 34.5% year to date, trading around $7.20 a share as of this writing. There's risk involved in investing in this company since it deals with a capital-intensive model, losses are widening, and ibuying hasn't been proven to be a secure business yet. But at this price and with its current growth rates, Offerpad might be a stock to consider for your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":82,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815867903,"gmtCreate":1630667340402,"gmtModify":1631891082283,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Up again&nbsp;","listText":"Up again&nbsp;","text":"Up again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/815867903","repostId":"1115885693","repostType":4,"repost":{"id":"1115885693","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630657884,"share":"https://www.laohu8.com/m/news/1115885693?lang=&edition=full","pubTime":"2021-09-03 16:31","market":"us","language":"en","title":"Meta Materials shares jumped 9.5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1115885693","media":"Tiger Newspress","summary":"Meta Materials shares jumped 9.5% in premarket trading.\nAs growth investors focus on companies with ","content":"<p>Meta&nbsp;Materials&nbsp;shares&nbsp;jumped&nbsp;9.5%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/6735d98c58dd37f7b480d596413f56f0\" tg-width=\"872\" tg-height=\"621\" referrerpolicy=\"no-referrer\">As growth investors focus on companies with high-end, innovative technologies, Meta Materials has come into focus. This is a company designed to be the next-generation growth stock investors are looking for. The company produces a range of high-performance nano composites and other functional materials powering the explosive technological growth our economy is seeing.</p>\n<p>Accordingly, Meta Materials is growing in interest among investors as a “picks and shovels” play on various strong secular catalysts. A speculative pick, Meta Materials provides investors with tremendous growth potential.</p>\n<p>However, another key catalyst appears to be driving MMAT stock. Let’s dive into what investors are focusing on right now.</p>\n<p>Potential short-squeeze stocks have been taking off once again this past week. For investors in Meta Materials, this is a good thing.</p>\n<p>It appears Meta Materials has made the short-squeeze list among many retail traders. However, yesteday, an&nbsp;<b>S3 Partners</b>&nbsp;executive outlined his short-squeeze thesis for MMAT stock. This call, via a&nbsp;<i>CNBC</i>&nbsp;interview, has unsurprisingly emboldened retail traders to jump into MMAT stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Materials shares jumped 9.5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Materials shares jumped 9.5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-03 16:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Meta&nbsp;Materials&nbsp;shares&nbsp;jumped&nbsp;9.5%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/6735d98c58dd37f7b480d596413f56f0\" tg-width=\"872\" tg-height=\"621\" referrerpolicy=\"no-referrer\">As growth investors focus on companies with high-end, innovative technologies, Meta Materials has come into focus. This is a company designed to be the next-generation growth stock investors are looking for. The company produces a range of high-performance nano composites and other functional materials powering the explosive technological growth our economy is seeing.</p>\n<p>Accordingly, Meta Materials is growing in interest among investors as a “picks and shovels” play on various strong secular catalysts. A speculative pick, Meta Materials provides investors with tremendous growth potential.</p>\n<p>However, another key catalyst appears to be driving MMAT stock. Let’s dive into what investors are focusing on right now.</p>\n<p>Potential short-squeeze stocks have been taking off once again this past week. For investors in Meta Materials, this is a good thing.</p>\n<p>It appears Meta Materials has made the short-squeeze list among many retail traders. However, yesteday, an&nbsp;<b>S3 Partners</b>&nbsp;executive outlined his short-squeeze thesis for MMAT stock. This call, via a&nbsp;<i>CNBC</i>&nbsp;interview, has unsurprisingly emboldened retail traders to jump into MMAT stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MMAT":"Meta Materials Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115885693","content_text":"Meta Materials shares jumped 9.5% in premarket trading.\nAs growth investors focus on companies with high-end, innovative technologies, Meta Materials has come into focus. This is a company designed to be the next-generation growth stock investors are looking for. The company produces a range of high-performance nano composites and other functional materials powering the explosive technological growth our economy is seeing.\nAccordingly, Meta Materials is growing in interest among investors as a “picks and shovels” play on various strong secular catalysts. A speculative pick, Meta Materials provides investors with tremendous growth potential.\nHowever, another key catalyst appears to be driving MMAT stock. Let’s dive into what investors are focusing on right now.\nPotential short-squeeze stocks have been taking off once again this past week. For investors in Meta Materials, this is a good thing.\nIt appears Meta Materials has made the short-squeeze list among many retail traders. However, yesteday, an S3 Partners executive outlined his short-squeeze thesis for MMAT stock. This call, via a CNBC interview, has unsurprisingly emboldened retail traders to jump into MMAT stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891674688,"gmtCreate":1628389067044,"gmtModify":1633747472583,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Maybe 🤔&nbsp;","listText":"Maybe 🤔&nbsp;","text":"Maybe 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/891674688","repostId":"1159872041","repostType":4,"repost":{"id":"1159872041","kind":"news","pubTimestamp":1628385224,"share":"https://www.laohu8.com/m/news/1159872041?lang=&edition=full","pubTime":"2021-08-08 09:13","market":"us","language":"en","title":"Tesla Stock: Headed to $1,200?","url":"https://stock-news.laohu8.com/highlight/detail?id=1159872041","media":"Motley Fool","summary":"Tesla deliveries more than doubled year over year in Q2.Rising demand for electric vehicles could benefit Tesla.Investors should exercise caution when it comes to analysts' price targets.It's been a wild year for Teslastock. When the year started, shares initially surged more than 20%. But the stock has now given up all of those gains, with a year-to-date return of negative 1%. This means the stock has significantly underperformed the S&P 500's 18% gain this year.In February,Piper Sandler analys","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Tesla deliveries more than doubled year over year in Q2.</li>\n <li>Rising demand for electric vehicles could benefit Tesla.</li>\n <li>Investors should exercise caution when it comes to analysts' price targets.</li>\n</ul>\n<p>It's been a wild year for&nbsp;<b>Tesla</b>(NASDAQ:TSLA)stock. When the year started, shares initially surged more than 20%. But the stock has now given up all of those gains, with a year-to-date return of negative 1%. This means the stock has significantly underperformed the&nbsp;<b>S&amp;P 500</b>'s 18% gain this year.</p>\n<p>But one analyst thinks the stock could take off.</p>\n<p><b>\"We still really like this stock.\"</b></p>\n<p>In February,<b>Piper Sandler</b>&nbsp;analyst Alexander Pottermade a bold call, boosting his 12-month price target for thegrowth stockfrom $515 to $1,200. He said Tesla deliveries could increase from 500,000 vehicles in 2020 to nearly 900,000 this year. Of course, this projection was made before global supply shortages worsened. Nevertheless, Tesla is growing extremely rapidly. The company's second-quarter deliveries more than doubled compared to the year-ago quarter, rising to 201,304.</p>\n<p>Following Tesla's second-quarter earnings release late last month, the analyst reiterated this target, noting that the company looks poised to benefit from market share gains, the monetization of the company's Autopilot software, and \"underappreciated opportunities\" in Tesla's energy business, which includes revenue from battery energy storage and solar energy generation products.</p>\n<p>Further, Potter pointed to Tesla's strong second-quarter operating margin of 11%, which he expects will see incremental improvement from Tesla's recently launched Autopilot subscription.</p>\n<p>On Aug. 3, Potter once again reiterated an overweight rating on the stock and a $1,200 price target, saying \"We still really like this stock.\" He pointed to growing demand for battery electric vehicles overall.</p>\n<p><b>So what gives?</b></p>\n<p>If shares could truly rise to $1,200, why do so many investors seem to think the stock is worth so much less (based on the stock's price of just under $700 at the time of this writing). After all, if $1,200 was generally viewed by investors as a likely outcome for Tesla stock within the next 12 months, shares would be trading significantly higher today.</p>\n<p>The issue boils down to the stock's forward-looking valuation. With a price-to-earnings ratio of about 370 at the time of this writing, Tesla shares are largely priced for strong growth for years to come. Since the company's valuation is based largely on profits far into the future, slight variances in views for Tesla's future growth trajectory yield dramatically different assumptions about the stock's intrinsic value today.</p>\n<p>Investors, therefore, shouldn't be quick to buy Tesla stock just because one analyst has a high price target for shares. Still, Potter does notably have some good points about Tesla's strong business momentum. Even Tesla itself reiterated guidance for vehicle deliveries to grow more than 50% this year -- and that guidance was provided during a time that many companies around the world (including Tesla) are negatively impacted by supply chain shortages. Further, Tesla management noted in its second-quarter update that demand for its vehicles was at an all-time high going into Q3.</p>\n<p>While a $1,200 price target for Tesla stock would be difficult to justify, shares may be trading low enough for investors to start a small position in the stock.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock: Headed to $1,200?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock: Headed to $1,200?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-08 09:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/07/tesla-stock-headed-to-1200/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nTesla deliveries more than doubled year over year in Q2.\nRising demand for electric vehicles could benefit Tesla.\nInvestors should exercise caution when it comes to analysts' price targets...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/07/tesla-stock-headed-to-1200/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/08/07/tesla-stock-headed-to-1200/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159872041","content_text":"Key Points\n\nTesla deliveries more than doubled year over year in Q2.\nRising demand for electric vehicles could benefit Tesla.\nInvestors should exercise caution when it comes to analysts' price targets.\n\nIt's been a wild year for Tesla(NASDAQ:TSLA)stock. When the year started, shares initially surged more than 20%. But the stock has now given up all of those gains, with a year-to-date return of negative 1%. This means the stock has significantly underperformed the S&P 500's 18% gain this year.\nBut one analyst thinks the stock could take off.\n\"We still really like this stock.\"\nIn February,Piper Sandler analyst Alexander Pottermade a bold call, boosting his 12-month price target for thegrowth stockfrom $515 to $1,200. He said Tesla deliveries could increase from 500,000 vehicles in 2020 to nearly 900,000 this year. Of course, this projection was made before global supply shortages worsened. Nevertheless, Tesla is growing extremely rapidly. The company's second-quarter deliveries more than doubled compared to the year-ago quarter, rising to 201,304.\nFollowing Tesla's second-quarter earnings release late last month, the analyst reiterated this target, noting that the company looks poised to benefit from market share gains, the monetization of the company's Autopilot software, and \"underappreciated opportunities\" in Tesla's energy business, which includes revenue from battery energy storage and solar energy generation products.\nFurther, Potter pointed to Tesla's strong second-quarter operating margin of 11%, which he expects will see incremental improvement from Tesla's recently launched Autopilot subscription.\nOn Aug. 3, Potter once again reiterated an overweight rating on the stock and a $1,200 price target, saying \"We still really like this stock.\" He pointed to growing demand for battery electric vehicles overall.\nSo what gives?\nIf shares could truly rise to $1,200, why do so many investors seem to think the stock is worth so much less (based on the stock's price of just under $700 at the time of this writing). After all, if $1,200 was generally viewed by investors as a likely outcome for Tesla stock within the next 12 months, shares would be trading significantly higher today.\nThe issue boils down to the stock's forward-looking valuation. With a price-to-earnings ratio of about 370 at the time of this writing, Tesla shares are largely priced for strong growth for years to come. Since the company's valuation is based largely on profits far into the future, slight variances in views for Tesla's future growth trajectory yield dramatically different assumptions about the stock's intrinsic value today.\nInvestors, therefore, shouldn't be quick to buy Tesla stock just because one analyst has a high price target for shares. Still, Potter does notably have some good points about Tesla's strong business momentum. Even Tesla itself reiterated guidance for vehicle deliveries to grow more than 50% this year -- and that guidance was provided during a time that many companies around the world (including Tesla) are negatively impacted by supply chain shortages. Further, Tesla management noted in its second-quarter update that demand for its vehicles was at an all-time high going into Q3.\nWhile a $1,200 price target for Tesla stock would be difficult to justify, shares may be trading low enough for investors to start a small position in the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":11,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809874668,"gmtCreate":1627361897154,"gmtModify":1633765707737,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"AMD good to buy ?","listText":"AMD good to buy ?","text":"AMD good to buy ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/809874668","repostId":"1190848120","repostType":4,"repost":{"id":"1190848120","kind":"news","pubTimestamp":1627356244,"share":"https://www.laohu8.com/m/news/1190848120?lang=&edition=full","pubTime":"2021-07-27 11:24","market":"us","language":"en","title":"AMD Reports Earnings Tuesday. It’s All About the Data Center.","url":"https://stock-news.laohu8.com/highlight/detail?id=1190848120","media":"Barrons","summary":"When chip designer Advanced Micro Devices reports earnings Tuesday after the closing bell, investors","content":"<p>When chip designer Advanced Micro Devices reports earnings Tuesday after the closing bell, investors are expecting a 266% increase in per-share profit and a near doubling in revenue.</p>\n<p>Amid chip shortages crippling the global economy, investors have lofty expectations for semiconductor businesses.</p>\n<p>For AMD (ticker: AMD), the company’s ability to top high expectations may come down to its revenue from data center chips. That data-center market is rich with opportunity for AMD, after the launch delay of a new advanced server chip from rival Intel (INTC).</p>\n<p>Jefferies analyst Mark Lipacis wrote that, according to his team’s industry checks, AMD’s Milan server chips are set to take a significant amount of market share from Intel in the second half of the year.</p>\n<p>AMD executives have issued consistently bullish guidance. In April, the company forecast that revenue would be up 86% in the second-quarter, to approximately $3.6 billion. Analysts currently expect second-quarter adjusted profit of 54 cents a share on revenue of $3.6 billion.</p>\n<p>Wall Street expects AMD to deliver computer and graphics segment revenue of $2.2 billion and enterprise, embedded, and semi-custom revenue of $1.4 billion. The company’s semi-custom business includes chips designed for new videogame consoles sold by Microsoft (MSFT) and Sony (SNE).</p>\n<p>AMD has previously said it expects full-year 2021 revenue to grow about 50% from last year.</p>\n<p>AMD’s growth potential could be limited by difficulties in obtaining materials and components necessary for chip making, as well as securing additional capacity from its contract manufacturers, including Taiwan Semiconductor Manufacturing (TSM). BMO Capital Markets analyst Ambrish Srivastava wrote that data center demand could be hurt by component shortages and some of the materials necessary to manufacture chips.</p>\n<p>Because AMD shares trade at a high multiple—42 times earnings estimates for the next 12 months—Srivastava said that the company would need to top Wall Street expectations by a “meaningful” amount and again raise its full-year guidance to move the stock higher.</p>\n<p>AMD has reported better-than-expected per-share profit for the past four quarters. It has missed revenue estimates only once in the past two years.</p>\n<p>Outsize expectations and bullish forecasts from executives haven’t done much to help AMD’s stock recently. After soaring in 2020, AMD shares are flat this year, while the PHLX Semiconductor index is up 17%.</p>\n<p>Among Wall Street analysts covering AMD, 25 rate the stock at Buy, 15 at Hold, and three at Sell. The average target price is $102.35, 11% above a recent close of $91.82.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD Reports Earnings Tuesday. It’s All About the Data Center.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD Reports Earnings Tuesday. It’s All About the Data Center.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/amd-reports-earnings-tuesday-its-all-about-the-data-center-51627339031?mod=hp_DAY_3><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When chip designer Advanced Micro Devices reports earnings Tuesday after the closing bell, investors are expecting a 266% increase in per-share profit and a near doubling in revenue.\nAmid chip ...</p>\n\n<a href=\"https://www.barrons.com/articles/amd-reports-earnings-tuesday-its-all-about-the-data-center-51627339031?mod=hp_DAY_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://www.barrons.com/articles/amd-reports-earnings-tuesday-its-all-about-the-data-center-51627339031?mod=hp_DAY_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190848120","content_text":"When chip designer Advanced Micro Devices reports earnings Tuesday after the closing bell, investors are expecting a 266% increase in per-share profit and a near doubling in revenue.\nAmid chip shortages crippling the global economy, investors have lofty expectations for semiconductor businesses.\nFor AMD (ticker: AMD), the company’s ability to top high expectations may come down to its revenue from data center chips. That data-center market is rich with opportunity for AMD, after the launch delay of a new advanced server chip from rival Intel (INTC).\nJefferies analyst Mark Lipacis wrote that, according to his team’s industry checks, AMD’s Milan server chips are set to take a significant amount of market share from Intel in the second half of the year.\nAMD executives have issued consistently bullish guidance. In April, the company forecast that revenue would be up 86% in the second-quarter, to approximately $3.6 billion. Analysts currently expect second-quarter adjusted profit of 54 cents a share on revenue of $3.6 billion.\nWall Street expects AMD to deliver computer and graphics segment revenue of $2.2 billion and enterprise, embedded, and semi-custom revenue of $1.4 billion. The company’s semi-custom business includes chips designed for new videogame consoles sold by Microsoft (MSFT) and Sony (SNE).\nAMD has previously said it expects full-year 2021 revenue to grow about 50% from last year.\nAMD’s growth potential could be limited by difficulties in obtaining materials and components necessary for chip making, as well as securing additional capacity from its contract manufacturers, including Taiwan Semiconductor Manufacturing (TSM). BMO Capital Markets analyst Ambrish Srivastava wrote that data center demand could be hurt by component shortages and some of the materials necessary to manufacture chips.\nBecause AMD shares trade at a high multiple—42 times earnings estimates for the next 12 months—Srivastava said that the company would need to top Wall Street expectations by a “meaningful” amount and again raise its full-year guidance to move the stock higher.\nAMD has reported better-than-expected per-share profit for the past four quarters. It has missed revenue estimates only once in the past two years.\nOutsize expectations and bullish forecasts from executives haven’t done much to help AMD’s stock recently. After soaring in 2020, AMD shares are flat this year, while the PHLX Semiconductor index is up 17%.\nAmong Wall Street analysts covering AMD, 25 rate the stock at Buy, 15 at Hold, and three at Sell. The average target price is $102.35, 11% above a recent close of $91.82.","news_type":1},"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809373726,"gmtCreate":1627350227865,"gmtModify":1633765850916,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Will hit always highly&nbsp;","listText":"Will hit always highly&nbsp;","text":"Will hit always highly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/809373726","repostId":"1153028059","repostType":4,"repost":{"id":"1153028059","kind":"news","pubTimestamp":1627340900,"share":"https://www.laohu8.com/m/news/1153028059?lang=&edition=full","pubTime":"2021-07-27 07:08","market":"us","language":"en","title":"Tesla sales surge 98%; company boosts margins on its less-costly electric cars","url":"https://stock-news.laohu8.com/highlight/detail?id=1153028059","media":"Reuters","summary":" -Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.Tesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.For the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operati","content":"<p>(Reuters) -Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.</p>\n<p>Tesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.</p>\n<p>For the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operation. Tesla boosted its performance by cutting features it said were unused or unneeded and raising U.S. vehicle prices.</p>\n<p>Shares of the world’s most valuable automaker rose 1.5% in extended trade.</p>\n<p>In a call with investors and analysts, Tesla executives said that volume production growth will depend on parts availability, and Musk cautioned the shortage of semiconductors will continue.</p>\n<p>“The global chip shortage situation remains quite serious,” Musk said.</p>\n<p>Still, Musk said Tesla expects to launch production this year of the Model Y SUV at factories under construction in Texas and Germany. He said the company expects battery cell suppliers to double production next year.</p>\n<p>Despite the pandemic and the supply chain crisis, Tesla posted record deliveries during the quarter, thanks to sales of cheaper models including Model 3 sedans and Model Ys.</p>\n<p>The carmaker, led by billionaire entrepreneur Elon Musk, said revenue jumped to $11.96 billion from $6.04 billion a year earlier, when its California factory was shut down for more than six weeks due to local lockdown orders to fight the pandemic.</p>\n<p>Analysts had expected revenue of about $11.3 billion, according to IBES data from Refinitiv.</p>\n<p>Excluding items, Tesla posted a profit of $1.45 per share, easily topping analyst expectations for a profit of 98 cents per share.</p>\n<p>Tesla said operating income rose with volume growth and cost reduction, which offset higher supply chain costs, lower regulatory credit revenue and other items including $23 million in losses on investment in cryptocurrency bitcoin.</p>\n<p>Tesla’s profitability has often relied on selling regulatory credits to other automakers, but in the second quarter, Tesla was profitable without these credits for the first time since the end of 2019. Its GAAP net income was $1.14 billion in the second quarter. Revenue from the credits only totaled $354 million.</p>\n<p>“Tesla impressed with its numbers, as most of its revenue came from vehicle sales,” Jesse Cohen, senior analyst at Investing.com, said.</p>\n<p>Carmaker Stellantis expects to achieve its European carbon dioxide (CO2) emissions targets this year without environmental credits bought from Tesla.</p>\n<p>Tesla said it said it has delayed the launch of the Semi truck program to 2022 to focus on starting factories and due to limited availability of battery cells and other parts this year.</p>\n<p>But the company’s new 4680 batteries are not ready for volume production; executives said it was difficult to predict when technological challenges would be resolved.</p>\n<p>In an aside, Musk said he “most likely will not be on earnings calls” going forward to discuss financial results with investors and analysts. These calls have been a colorful quarterly ritual Musk has used for discourses on Tesla technology, or to fire back at rivals or critics.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla sales surge 98%; company boosts margins on its less-costly electric cars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla sales surge 98%; company boosts margins on its less-costly electric cars\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/tesla-results/update-4-tesla-sales-surge-98-company-boosts-margins-on-its-less-costly-electric-cars-idUSL4N2P23I5><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on ...</p>\n\n<a href=\"https://www.reuters.com/article/tesla-results/update-4-tesla-sales-surge-98-company-boosts-margins-on-its-less-costly-electric-cars-idUSL4N2P23I5\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.reuters.com/article/tesla-results/update-4-tesla-sales-surge-98-company-boosts-margins-on-its-less-costly-electric-cars-idUSL4N2P23I5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153028059","content_text":"(Reuters) -Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.\nTesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.\nFor the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operation. Tesla boosted its performance by cutting features it said were unused or unneeded and raising U.S. vehicle prices.\nShares of the world’s most valuable automaker rose 1.5% in extended trade.\nIn a call with investors and analysts, Tesla executives said that volume production growth will depend on parts availability, and Musk cautioned the shortage of semiconductors will continue.\n“The global chip shortage situation remains quite serious,” Musk said.\nStill, Musk said Tesla expects to launch production this year of the Model Y SUV at factories under construction in Texas and Germany. He said the company expects battery cell suppliers to double production next year.\nDespite the pandemic and the supply chain crisis, Tesla posted record deliveries during the quarter, thanks to sales of cheaper models including Model 3 sedans and Model Ys.\nThe carmaker, led by billionaire entrepreneur Elon Musk, said revenue jumped to $11.96 billion from $6.04 billion a year earlier, when its California factory was shut down for more than six weeks due to local lockdown orders to fight the pandemic.\nAnalysts had expected revenue of about $11.3 billion, according to IBES data from Refinitiv.\nExcluding items, Tesla posted a profit of $1.45 per share, easily topping analyst expectations for a profit of 98 cents per share.\nTesla said operating income rose with volume growth and cost reduction, which offset higher supply chain costs, lower regulatory credit revenue and other items including $23 million in losses on investment in cryptocurrency bitcoin.\nTesla’s profitability has often relied on selling regulatory credits to other automakers, but in the second quarter, Tesla was profitable without these credits for the first time since the end of 2019. Its GAAP net income was $1.14 billion in the second quarter. Revenue from the credits only totaled $354 million.\n“Tesla impressed with its numbers, as most of its revenue came from vehicle sales,” Jesse Cohen, senior analyst at Investing.com, said.\nCarmaker Stellantis expects to achieve its European carbon dioxide (CO2) emissions targets this year without environmental credits bought from Tesla.\nTesla said it said it has delayed the launch of the Semi truck program to 2022 to focus on starting factories and due to limited availability of battery cells and other parts this year.\nBut the company’s new 4680 batteries are not ready for volume production; executives said it was difficult to predict when technological challenges would be resolved.\nIn an aside, Musk said he “most likely will not be on earnings calls” going forward to discuss financial results with investors and analysts. These calls have been a colorful quarterly ritual Musk has used for discourses on Tesla technology, or to fire back at rivals or critics.","news_type":1},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172745819,"gmtCreate":1626996555231,"gmtModify":1633769045376,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"themes":[],"htmlText":"Lower to 50?","listText":"Lower to 50?","text":"Lower to 50?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/172745819","repostId":"2153670096","repostType":4,"repost":{"id":"2153670096","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1626996120,"share":"https://www.laohu8.com/m/news/2153670096?lang=&edition=full","pubTime":"2021-07-23 07:22","market":"us","language":"en","title":"Intel stock ticks lower as outlook barely clears Wall Street expectations following beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2153670096","media":"Dow Jones","summary":"Revenue tops estimates while declining for fourth straight quarter\nIntel Corp. shares weakened in th","content":"<p>Revenue tops estimates while declining for fourth straight quarter</p>\n<p>Intel Corp. shares weakened in the extended session Thursday after the chip maker topped expectations, but its outlook barely surpassed the average forecast from Wall Street analysts.</p>\n<p>Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> shares were last down 1% in the extended session, following an initial 3% uptick in after-hours trading. Shares closed down 0.5% in the regular session at $55.96.</p>\n<p>Intel reported second-quarter net income of $5.06 billion, or $1.24 a share, compared with $5.11 billion, or $1.19 a share, in the year-ago period. After adjusting for acquisition-related expenses and other items, Intel reported earnings of $1.28 a share, compared with $1.23 a share from a year ago.</p>\n<p>Revenue declined to $19.63 billion from $19.73 billion in the year-ago quarter, for a fourth straight quarter of year-over-year revenue declines, but topped its own and analysts' estimates. Excluding the company's memory business, revenue was $18.5 billion. Analysts had estimated adjusted earnings of $1.07 a share on revenue of $17.81 billion, while Intel had forecast adjusted earnings of $1.05 a share on revenue of $18.9 billion, or $17.8 billion when removing the memory business it was divesting.</p>\n<p>\"Our second-quarter results show that our momentum is building, our execution is improving, and customers continue to choose us for leadership products,\" said Intel Chief Executive Pat Gelsinger in a statement.</p>\n<p>For the third quarter, Intel forecast revenue of about $19.1 billion, or $18.2 billion when removing the memory business, and GAAP earnings of $1.08 a share and non-GAAP earnings of $1.10 a share. Analysts on average expected adjusted third-quarter earnings of $1.09 a share on revenue of $18.11 billion.</p>\n<p>Intel's data-center group revenue declined 9% to $6.5 billion, while analysts surveyed by FactSet expected $5.84 billion.</p>\n<p>Intel's largest segment -- client-computing, the traditional PC group -- rose 6% to $10.1 billion, with analysts expecting $10.03 billion.</p>\n<p>Intel reported that nonvolatile memory-solutions revenue fell 34% to $1.1 billion, while Wall Street expected $690.8 million, and \"Internet of Things,\" or IoT, revenue rose 47% to $984 million, compared with an expected $901.5 million. <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a> revenue soared 124% to $327 million, but the Street had expected $361.4 million.</p>\n<p>Over the past 12 months, Intel stock has fallen 8%. Over the same period, the Dow Jones Industrial Average -- which counts Intel as a component -- has gained 29%, the S&amp;P 500 index has climbed 33%, the tech-heavy Nasdaq Composite Index has advanced 37%, and the PHLX Semiconductor Index has surged 55%.</p>\n<p>On Wednesday, Texas Instruments Inc. <a href=\"https://laohu8.com/S/TXN\">$(TXN)$</a>kicked off earnings season for U.S. chip makers, amid a global semiconductor shortage.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel stock ticks lower as outlook barely clears Wall Street expectations following beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel stock ticks lower as outlook barely clears Wall Street expectations following beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-23 07:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Revenue tops estimates while declining for fourth straight quarter</p>\n<p>Intel Corp. shares weakened in the extended session Thursday after the chip maker topped expectations, but its outlook barely surpassed the average forecast from Wall Street analysts.</p>\n<p>Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> shares were last down 1% in the extended session, following an initial 3% uptick in after-hours trading. Shares closed down 0.5% in the regular session at $55.96.</p>\n<p>Intel reported second-quarter net income of $5.06 billion, or $1.24 a share, compared with $5.11 billion, or $1.19 a share, in the year-ago period. After adjusting for acquisition-related expenses and other items, Intel reported earnings of $1.28 a share, compared with $1.23 a share from a year ago.</p>\n<p>Revenue declined to $19.63 billion from $19.73 billion in the year-ago quarter, for a fourth straight quarter of year-over-year revenue declines, but topped its own and analysts' estimates. Excluding the company's memory business, revenue was $18.5 billion. Analysts had estimated adjusted earnings of $1.07 a share on revenue of $17.81 billion, while Intel had forecast adjusted earnings of $1.05 a share on revenue of $18.9 billion, or $17.8 billion when removing the memory business it was divesting.</p>\n<p>\"Our second-quarter results show that our momentum is building, our execution is improving, and customers continue to choose us for leadership products,\" said Intel Chief Executive Pat Gelsinger in a statement.</p>\n<p>For the third quarter, Intel forecast revenue of about $19.1 billion, or $18.2 billion when removing the memory business, and GAAP earnings of $1.08 a share and non-GAAP earnings of $1.10 a share. Analysts on average expected adjusted third-quarter earnings of $1.09 a share on revenue of $18.11 billion.</p>\n<p>Intel's data-center group revenue declined 9% to $6.5 billion, while analysts surveyed by FactSet expected $5.84 billion.</p>\n<p>Intel's largest segment -- client-computing, the traditional PC group -- rose 6% to $10.1 billion, with analysts expecting $10.03 billion.</p>\n<p>Intel reported that nonvolatile memory-solutions revenue fell 34% to $1.1 billion, while Wall Street expected $690.8 million, and \"Internet of Things,\" or IoT, revenue rose 47% to $984 million, compared with an expected $901.5 million. <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a> revenue soared 124% to $327 million, but the Street had expected $361.4 million.</p>\n<p>Over the past 12 months, Intel stock has fallen 8%. Over the same period, the Dow Jones Industrial Average -- which counts Intel as a component -- has gained 29%, the S&amp;P 500 index has climbed 33%, the tech-heavy Nasdaq Composite Index has advanced 37%, and the PHLX Semiconductor Index has surged 55%.</p>\n<p>On Wednesday, Texas Instruments Inc. <a href=\"https://laohu8.com/S/TXN\">$(TXN)$</a>kicked off earnings season for U.S. chip makers, amid a global semiconductor shortage.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","INTC":"英特尔","09086":"华夏纳指-U"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153670096","content_text":"Revenue tops estimates while declining for fourth straight quarter\nIntel Corp. shares weakened in the extended session Thursday after the chip maker topped expectations, but its outlook barely surpassed the average forecast from Wall Street analysts.\nIntel $(INTC)$ shares were last down 1% in the extended session, following an initial 3% uptick in after-hours trading. Shares closed down 0.5% in the regular session at $55.96.\nIntel reported second-quarter net income of $5.06 billion, or $1.24 a share, compared with $5.11 billion, or $1.19 a share, in the year-ago period. After adjusting for acquisition-related expenses and other items, Intel reported earnings of $1.28 a share, compared with $1.23 a share from a year ago.\nRevenue declined to $19.63 billion from $19.73 billion in the year-ago quarter, for a fourth straight quarter of year-over-year revenue declines, but topped its own and analysts' estimates. Excluding the company's memory business, revenue was $18.5 billion. Analysts had estimated adjusted earnings of $1.07 a share on revenue of $17.81 billion, while Intel had forecast adjusted earnings of $1.05 a share on revenue of $18.9 billion, or $17.8 billion when removing the memory business it was divesting.\n\"Our second-quarter results show that our momentum is building, our execution is improving, and customers continue to choose us for leadership products,\" said Intel Chief Executive Pat Gelsinger in a statement.\nFor the third quarter, Intel forecast revenue of about $19.1 billion, or $18.2 billion when removing the memory business, and GAAP earnings of $1.08 a share and non-GAAP earnings of $1.10 a share. Analysts on average expected adjusted third-quarter earnings of $1.09 a share on revenue of $18.11 billion.\nIntel's data-center group revenue declined 9% to $6.5 billion, while analysts surveyed by FactSet expected $5.84 billion.\nIntel's largest segment -- client-computing, the traditional PC group -- rose 6% to $10.1 billion, with analysts expecting $10.03 billion.\nIntel reported that nonvolatile memory-solutions revenue fell 34% to $1.1 billion, while Wall Street expected $690.8 million, and \"Internet of Things,\" or IoT, revenue rose 47% to $984 million, compared with an expected $901.5 million. Mobileye revenue soared 124% to $327 million, but the Street had expected $361.4 million.\nOver the past 12 months, Intel stock has fallen 8%. Over the same period, the Dow Jones Industrial Average -- which counts Intel as a component -- has gained 29%, the S&P 500 index has climbed 33%, the tech-heavy Nasdaq Composite Index has advanced 37%, and the PHLX Semiconductor Index has surged 55%.\nOn Wednesday, Texas Instruments Inc. $(TXN)$kicked off earnings season for U.S. chip makers, amid a global semiconductor shortage.","news_type":1},"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}